

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>In vivo genome editing in animals using... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-2153/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-2153" />
    
            <meta name="description" content="Read the original article in full on F1000Research: In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease" />
    
            <meta name="og:title" content="F1000Research Article: &lt;i&gt;In vivo&lt;/i&gt; genome editing in animals using AAV-CRISPR system: applications to translational research of human disease.">
            <meta name="og:description" content="Read the latest article version by Cia-Hin Lau, Yousin Suh, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12130">
            <meta name="article-id" content="11243">
            <meta name="dc.title" content="&lt;i&gt;In vivo&lt;/i&gt; genome editing in animals using AAV-CRISPR system: applications to translational research of human disease">
            <meta name="dc.description" content="Adeno-associated virus (AAV) has shown promising therapeutic efficacy with a good safety profile in a wide range of animal models and human clinical trials. With the advent of clustered regulatory interspaced short palindromic repeat (CRISPR)-based genome-editing technologies, AAV provides one of the most suitable viral vectors to package, deliver, and express CRISPR components for targeted gene editing. Recent discoveries of smaller Cas9 orthologues have enabled the packaging of Cas9 nuclease and its chimeric guide RNA into a single AAV delivery vehicle for robust in vivo genome editing. Here, we discuss how the combined use of small Cas9 orthologues, tissue-specific minimal promoters, AAV serotypes, and different routes of administration has advanced the development of efficient and precise in vivo genome editing and comprehensively review the various AAV-CRISPR systems that have been effectively used in animals. We then discuss the clinical implications and potential strategies to overcome off-target effects, immunogenicity, and toxicity associated with CRISPR components and AAV delivery vehicles. Finally, we discuss ongoing non-viral-based ex vivo gene therapy clinical trials to underscore the current challenges and future prospects of CRISPR/Cas9 delivery for human therapeutics.">
            <meta name="dc.subject" content="CRISPR/Cas9 complex, genome editing, adeno-associated virus, ">
            <meta name="dc.creator" content="Lau, Cia-Hin">
            <meta name="dc.creator" content="Suh, Yousin">
            <meta name="dc.date" content="2017/12/20">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11243.1">
            <meta name="dc.source" content="F1000Research 2017 6:2153">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="CRISPR/Cas9 complex">
            <meta name="prism.keyword" content="genome editing">
            <meta name="prism.keyword" content="adeno-associated virus">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/12/20">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="2153">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11243.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-2153">
            <meta name="citation_title" content="&lt;i&gt;In vivo&lt;/i&gt; genome editing in animals using AAV-CRISPR system: applications to translational research of human disease">
            <meta name="citation_abstract" content="Adeno-associated virus (AAV) has shown promising therapeutic efficacy with a good safety profile in a wide range of animal models and human clinical trials. With the advent of clustered regulatory interspaced short palindromic repeat (CRISPR)-based genome-editing technologies, AAV provides one of the most suitable viral vectors to package, deliver, and express CRISPR components for targeted gene editing. Recent discoveries of smaller Cas9 orthologues have enabled the packaging of Cas9 nuclease and its chimeric guide RNA into a single AAV delivery vehicle for robust in vivo genome editing. Here, we discuss how the combined use of small Cas9 orthologues, tissue-specific minimal promoters, AAV serotypes, and different routes of administration has advanced the development of efficient and precise in vivo genome editing and comprehensively review the various AAV-CRISPR systems that have been effectively used in animals. We then discuss the clinical implications and potential strategies to overcome off-target effects, immunogenicity, and toxicity associated with CRISPR components and AAV delivery vehicles. Finally, we discuss ongoing non-viral-based ex vivo gene therapy clinical trials to underscore the current challenges and future prospects of CRISPR/Cas9 delivery for human therapeutics.">
            <meta name="citation_description" content="Adeno-associated virus (AAV) has shown promising therapeutic efficacy with a good safety profile in a wide range of animal models and human clinical trials. With the advent of clustered regulatory interspaced short palindromic repeat (CRISPR)-based genome-editing technologies, AAV provides one of the most suitable viral vectors to package, deliver, and express CRISPR components for targeted gene editing. Recent discoveries of smaller Cas9 orthologues have enabled the packaging of Cas9 nuclease and its chimeric guide RNA into a single AAV delivery vehicle for robust in vivo genome editing. Here, we discuss how the combined use of small Cas9 orthologues, tissue-specific minimal promoters, AAV serotypes, and different routes of administration has advanced the development of efficient and precise in vivo genome editing and comprehensively review the various AAV-CRISPR systems that have been effectively used in animals. We then discuss the clinical implications and potential strategies to overcome off-target effects, immunogenicity, and toxicity associated with CRISPR components and AAV delivery vehicles. Finally, we discuss ongoing non-viral-based ex vivo gene therapy clinical trials to underscore the current challenges and future prospects of CRISPR/Cas9 delivery for human therapeutics.">
            <meta name="citation_keywords" content="CRISPR/Cas9 complex, genome editing, adeno-associated virus, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Cia-Hin Lau">
            <meta name="citation_author_institution" content="Department of Mechanical and Biomedical Engineering, City University of Hong Kong, Hong Kong, SAR, China">
            <meta name="citation_author" content="Yousin Suh">
            <meta name="citation_author_institution" content="Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, USA">
            <meta name="citation_author_institution" content="Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, New York, USA">
            <meta name="citation_author_institution" content="Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA">
            <meta name="citation_author_institution" content="Institute for Aging Research, Albert Einstein College of Medicine, Bronx, New York, USA">
            <meta name="citation_publication_date" content="2017/12/20">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="2153">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11243.1">
            <meta name="citation_firstpage" content="2153">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-2153/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-2153.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12130 /> <input type=hidden id=articleId name=articleId value=11243 /> <input type=hidden id=xmlUrl value="/articles/6-2153/v1/xml"/> <input type=hidden id=xmlFileName value="-6-2153-v1.xml"> <input type=hidden id=article_uuid value=1afb21ab-ebd6-4340-9118-10beb7348b60 /> <input type=hidden id=referer value=""/> <input type="hidden" id="meta-article-title" value="<i>In vivo</i> genome editing in animals using AAV-CRISPR system: applications to translational research of human disease" /> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11243.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11243.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-2153"
  },
  "headline": "In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human...",
  "datePublished": "2017-12-20T11:38:14",
  "dateModified": "2017-12-20T11:38:14",
  "author": [
    {
      "@type": "Person",
      "name": "Cia-Hin Lau"
    },    {
      "@type": "Person",
      "name": "Yousin Suh"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Adeno-associated virus (AAV) has shown promising therapeutic efficacy with a good safety profile in a wide range of animal models and human clinical trials. With the advent of clustered regulatory interspaced short palindromic repeat (CRISPR)-based genome-editing technologies, AAV provides one of the most suitable viral vectors to package, deliver, and express CRISPR components for targeted gene editing. Recent discoveries of smaller Cas9 orthologues have enabled the packaging of Cas9 nuclease and its chimeric guide RNA into a single AAV delivery vehicle for robust in vivo genome editing. Here, we discuss how the combined use of small Cas9 orthologues, tissue-specific minimal promoters, AAV serotypes, and different routes of administration has advanced the development of efficient and precise in vivo genome editing and comprehensively review the various AAV-CRISPR systems that have been effectively used in animals. We then discuss the clinical implications and potential strategies to overcome off-target effects, immunogenicity, and toxicity associated with CRISPR components and AAV delivery vehicles. Finally, we discuss ongoing non-viral-based ex vivo gene therapy clinical trials to underscore the current challenges and future prospects of CRISPR/Cas9 delivery for human therapeutics."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-2153",
            "name": "In vivo genome editing in animals using AAV-CRISPR system: applications..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> In vivo genome editing in animals using AAV-CRISPR system: applications... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12130 data-id=11243 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11243.1" data-recommended="" data-doi="10.12688/f1000research.11243.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-2153/v1/pdf?article_uuid=1afb21ab-ebd6-4340-9118-10beb7348b60" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11243-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11243-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11243-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Lau CH and Suh Y. <i>In vivo</i> genome editing in animals using AAV-CRISPR system: applications to translational research of human disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2153 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11243.1" target=_blank>https://doi.org/10.12688/f1000research.11243.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11243-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11243 id=track-article-signin-11243 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11243?target=/articles/6-2153">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12130 /> <input name=articleId type=hidden value=11243 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1><i>In vivo</i> genome editing in animals using AAV-CRISPR system: applications to translational research of human disease</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:lauciahin_4275@yahoo.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Cia-Hin Lau</span></a><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:yousin.suh@einstein.yu.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Yousin Suh</span></a><a href="https://orcid.org/0000-0002-4528-0363" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4528-0363</div><sup>2-5</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:lauciahin_4275@yahoo.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Cia-Hin Lau</span></a><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:yousin.suh@einstein.yu.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Yousin Suh</span></a><a href="http://orcid.org/0000-0002-4528-0363" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4528-0363</div><sup>2-5</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 20 Dec 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11243.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Mechanical and Biomedical Engineering, City University of Hong Kong, Hong Kong, SAR, China<br/> <sup>2</sup> Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, USA<br/> <sup>3</sup> Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, New York, USA<br/> <sup>4</sup> Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA<br/> <sup>5</sup> Institute for Aging Research, Albert Einstein College of Medicine, Bronx, New York, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29021-29026></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29020-29027></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Adeno-associated virus (AAV) has shown promising therapeutic efficacy with a good safety profile in a wide range of animal models and human clinical trials. With the advent of clustered regulatory interspaced short palindromic repeat (CRISPR)-based genome-editing technologies, AAV provides one of the most suitable viral vectors to package, deliver, and express CRISPR components for targeted gene editing. Recent discoveries of smaller Cas9 orthologues have enabled the packaging of Cas9 nuclease and its chimeric guide RNA into a single AAV delivery vehicle for robust <i>in vivo</i> genome editing. Here, we discuss how the combined use of small Cas9 orthologues, tissue-specific minimal promoters, AAV serotypes, and different routes of administration has advanced the development of efficient and precise <i>in vivo</i> genome editing and comprehensively review the various AAV-CRISPR systems that have been effectively used in animals. We then discuss the clinical implications and potential strategies to overcome off-target effects, immunogenicity, and toxicity associated with CRISPR components and AAV delivery vehicles. Finally, we discuss ongoing non-viral-based <i>ex vivo</i> gene therapy clinical trials to underscore the current challenges and future prospects of CRISPR/Cas9 delivery for human therapeutics. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> CRISPR/Cas9 complex, genome editing, adeno-associated virus, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Cia-Hin Lau (<a href="mailto:lauciahin_4275@yahoo.com">lauciahin_4275@yahoo.com</a>) <br> Yousin Suh (<a href="mailto:yousin.suh@einstein.yu.edu">yousin.suh@einstein.yu.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Cia-Hin Lau, Yousin Suh </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was funded by National Institutes of Health grants AG017242, GM104459, and CA180126 (to Yousin Suh). <br/> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Lau CH and Suh Y. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Lau CH and Suh Y. <i>In vivo</i> genome editing in animals using AAV-CRISPR system: applications to translational research of human disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2153 (<a href="https://doi.org/10.12688/f1000research.11243.1" target=_blank>https://doi.org/10.12688/f1000research.11243.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 20 Dec 2017, <b>6</b>(F1000 Faculty Rev):2153 (<a href="https://doi.org/10.12688/f1000research.11243.1" target=_blank>https://doi.org/10.12688/f1000research.11243.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 20 Dec 2017, <b>6</b>(F1000 Faculty Rev):2153 (<a href="https://doi.org/10.12688/f1000research.11243.1" target=_blank>https://doi.org/10.12688/f1000research.11243.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d2623e218>Introduction</h2><p class="" id=d2623e221>CRISPR (clustered regulatory interspaced short palindromic repeat)/Cas9-based RNA-guided DNA endonuclease is transforming biomedical science research and has quickly become the preferred genome-editing platform for interrogating endogenous gene function <i>in vivo</i><sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. The CRISPR-based genome-editing tool has revolutionized the gene-editing technique because of its simplicity in target design, affordability, high efficiency, versatility, and multiplexing capability<sup><a href="#ref-3">3</a></sup>. The commonly used CRISPR system can be implemented in mammalian cells by co-expressing Cas9 nuclease along with chimeric guide RNA (gRNA), which is derived from a synthetic fusion of the CRISPR RNA array (crRNA) and trans-activating crRNA (tracrRNA)<sup><a href="#ref-3">3</a></sup>. The target site sequence of gRNA needs to be immediately followed by an optimal protospacer adjacent motif (PAM) sequence according to the species-derived Cas9 nuclease used at the 3′ end<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. The background of and the recent developments in the CRISPR-based targeted genome-editing toolboxes have been extensively reviewed recently<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a>,<a href="#ref-6">6</a></sup>. Various applications of CRISPR technologies for genome engineering and medical research have also been reviewed recently<sup><a href="#ref-2">2</a>,<a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>.</p><p class="" id=d2623e269>The CRISPR/Cas9 complex can be introduced into the cell in the forms of DNA, messenger RNA (mRNA), or protein<sup><a href="#ref-8">8</a></sup>. The DNA encoding Cas9 and gRNA can be delivered into the cell using the plasmid and viral expression vectors<sup><a href="#ref-8">8</a></sup>. Through microinjection, liposome-mediated transfection, electroporation, or nucleofection<sup><a href="#ref-9">9</a></sup>, several recent studies have shown that the delivery format of active Cas9 protein/gRNA ribonucleoprotein (RNP) complex has lower off-target effects due to rapid clearance of RNPs from the cell<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a></sup> and rapid gene editing as they cleave chromosomal DNA almost immediately after delivery<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup> as compared with plasmid DNA transfection. However, the delivery formats of mRNA and protein pose certain technical challenges <i>in vivo</i>. For example, many of the genetic brain disorders affect very large brain areas and more than a single structure in the brain<sup><a href="#ref-11">11</a></sup>. Therefore, global gene delivery to the central nervous system is a key to achieve effective therapies for neurological disorders. Although a recent study has successfully demonstrated genome editing in the mouse brain by local delivery of RNPs<sup><a href="#ref-12">12</a></sup>, it is technically challenging to deliver the RNPs globally to the central nervous system. Thus, the viral-based <i>in vivo</i> genome editing remains a popular choice to achieve stable or elevated expression of Cas9 and single-guide RNA (sgRNA) required for establishing animal disease models and therapeutic gene editing in animals. Indeed, it has been demonstrated that systemic delivery of adeno-associated virus (AAV) vectors enabled uniform and broad vector distribution, and subsequently led to extensive and widespread transgene expression in the adult mouse central nervous system<sup><a href="#ref-13">13</a>–<a href="#ref-15">15</a></sup>.</p><p class="" id=d2623e320>Animal models are preferred over cell models, as they help understand disease mechanisms at the physiological and systemic levels. Somatic mutagenesis via <i>in vivo</i> genome editing provides an ideal platform to accelerate the generation of transgenic animals for rapid exploration of human diseases and correcting genetic defects in gene therapy. <i>In vivo</i> genome editing also avoids laborious germline targeting and high costs of maintaining transgenic neonates through adulthood in animals with a long life span. Obviously, somatic mutagenesis in adult animals has proven technically more challenging than gene editing of one-cell-stage embryos or zygotes or pluripotent stem cells. The major hurdle is to efficiently deliver the CRISPR components <i>in vivo</i>. To date, various viral, non-viral (for example, lipid nanoparticles), and physical (for example, hydrodynamic injection) based delivery approaches of the CRISPR/Cas9 complex have been adopted for <i>in vivo</i> genome editing. The pros and cons of these delivery methods have been extensively reviewed recently<sup><a href="#ref-16">16</a>–<a href="#ref-18">18</a></sup>.</p><p class="" id=d2623e342>Given the great potential of viral vectors in gene and cell therapy, five major classes of viral vectors—retroviruses<sup><a href="#ref-19">19</a></sup>, lentiviruses<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>, adenoviruses<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>, AAVs<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>, and baculoviruses<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>—have been employed to deliver CRISPR components into mammalian cells for targeted genome editing. The advantages and disadvantages of using these viral vectors for <i>in vivo</i> delivery of the CRISPR transgenes have been extensively reviewed<sup><a href="#ref-24">24</a>,<a href="#ref-28">28</a>–<a href="#ref-30">30</a></sup>. In <a href="#T1">Table 1</a>, we listed general characteristics and applications of various viral delivery vectors. Among these, the AAV vector is the overall focus of this review. The AAV system provides major advantages for research and therapeutics, including a very mild immune response and toxicity elicited by AAV in animal models. Moreover, AAVs remain primarily episomal upon transduction, avoiding random integration of the viral genetic materials into the host genome that can disrupt neighboring gene function and cause insertional mutagenesis<sup><a href="#ref-31">31</a></sup>. Indeed, there has been no reported case of disease caused by AAV in humans<sup><a href="#ref-31">31</a></sup>. Additionally, AAV can exist long-term as concatemers in non-dividing cells for stable transgene expressions<sup><a href="#ref-31">31</a></sup>. Given a good safety profile of AAV and therapeutic efficacy in a wide range of animal models and human clinical trials (ClinicalTrials.gov), AAV is thought to be one of the most suitable viral vectors for gene therapeutic applications and gene transfer <i>in vivo</i>. Furthermore, there is a wide range of AAV serotypes that can be selected to infect specific tissues <i>in vivo</i>. For these reasons, here, we provide an overview of the state of the art of various AAV-CRISPR systems as well as their principal vector designs for <i>in vivo</i> genome editing in animals. Senís and colleagues were amongst the first to exploit and demonstrate the use of the AAV vectors to package, deliver, and express CRISPR components for targeted gene editing in hard-to-transfect cells and the liver of adult mice<sup><a href="#ref-32">32</a></sup>. Subsequently, an increasing number of the studies used AAV vectors to deliver the CRISPR components into animals for <i>in vivo</i> genome editing. Of note, for certain applications such as packaging of a very large transgene<sup><a href="#ref-29">29</a>,<a href="#ref-33">33</a></sup>, genome-wide screening<sup><a href="#ref-20">20</a>,<a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>, and production of vaccines and recombinant proteins<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>, the other viral vectors may be a better option. However, in-depth discussions of the other viral delivery vehicles for the CRISPR components are beyond the scope of this review.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Viral delivery vectors for the CRISPR/Cas9 complex.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2623e460 class=n-a></a><thead><a name=d2623e462 class=n-a></a><tr><a name=d2623e464 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e466 class=n-a></a>Characteristics for a typical<br class=br>vector</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e471 class=n-a></a>Retrovirus<sup><a href="#ref-19">19</a>,<a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e483 class=n-a></a>Lentivirus<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a>,<a href="#ref-38">38</a>,<a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e501 class=n-a></a>Adenovirus<sup><a href="#ref-22">22</a>,<a href="#ref-42">42</a>–<a href="#ref-48">48</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e513 class=n-a></a>Adeno-associated<br class=br>virus<sup><a href="#ref-30">30</a>,<a href="#ref-32">32</a>,<a href="#ref-49">49</a>–<a href="#ref-52">52</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e531 class=n-a></a>Baculovirus<sup><a href="#ref-27">27</a>,<a href="#ref-29">29</a>,<a href="#ref-53">53</a></sup></th></tr></thead><tbody><a name=d2623e545 class=n-a></a><tr><a name=d2623e547 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e549 class=n-a></a>Common viral type</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e552 class=n-a></a>γ-retroviruses</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e555 class=n-a></a>HIV-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e558 class=n-a></a>Ad5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e561 class=n-a></a>AAV2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e565 class=n-a></a>AcMNPV</td></tr><tr><a name=d2623e569 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e571 class=n-a></a>Viral envelope</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e574 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e577 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e580 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e583 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e587 class=n-a></a>Yes</td></tr><tr><a name=d2623e591 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e593 class=n-a></a>Nucleocapsid shape</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e596 class=n-a></a>Icosahedral</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e599 class=n-a></a>Icosahedral</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e602 class=n-a></a>Icosahedral</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e605 class=n-a></a>Icosahedral</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e609 class=n-a></a>Rod</td></tr><tr><a name=d2623e613 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e615 class=n-a></a>Viral size</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e618 class=n-a></a>80–130 nm</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e621 class=n-a></a>80–130 nm</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e624 class=n-a></a>70–105 nm</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e627 class=n-a></a>18–26 nm</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e631 class=n-a></a>250–300 nm<br class=br>30–60 nm</td></tr><tr><a name=d2623e637 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e639 class=n-a></a>Viral genome structure</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e642 class=n-a></a>Linear ssRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e645 class=n-a></a>Linear ssRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e648 class=n-a></a>Linear dsDNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e651 class=n-a></a>Linear ssDNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e655 class=n-a></a>Circular dsDNA</td></tr><tr><a name=d2623e660 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e662 class=n-a></a>Viral genome size</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e665 class=n-a></a>8.3 kb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e668 class=n-a></a>9.7 kb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e671 class=n-a></a>36 kb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e674 class=n-a></a>4.7 kb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e678 class=n-a></a>80–180 kb</td></tr><tr><a name=d2623e682 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e684 class=n-a></a>Packaging capacity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e687 class=n-a></a>&lt;8.0 kb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e690 class=n-a></a>&lt;8.0 kb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e693 class=n-a></a>&lt;30 kb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e696 class=n-a></a>&lt;4.5 kb</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e700 class=n-a></a>&gt;38 kb</td></tr><tr><a name=d2623e704 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e706 class=n-a></a>Transgene is flanked by</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e709 class=n-a></a>LTRs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e712 class=n-a></a>LTRs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e715 class=n-a></a>ITRs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e718 class=n-a></a>ITRs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e722 class=n-a></a>Tn7s</td></tr><tr><a name=d2623e726 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e728 class=n-a></a>Viral generation approach</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e731 class=n-a></a>Triple-plasmid transfection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e734 class=n-a></a>Triple-plasmid transfection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e737 class=n-a></a>Homologous recombination</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e740 class=n-a></a>Triple-plasmid transfection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e744 class=n-a></a>Site-specific transposition</td></tr><tr><a name=d2623e748 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e750 class=n-a></a>Competent cell used</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e753 class=n-a></a>Stbl3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e756 class=n-a></a>Stbl3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e759 class=n-a></a>AdEasier-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e762 class=n-a></a>Stbl3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e766 class=n-a></a>DH10Bac</td></tr><tr><a name=d2623e770 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e772 class=n-a></a>Host cells used</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e775 class=n-a></a>HEK293T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e778 class=n-a></a>HEK293T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e781 class=n-a></a>HEK293T or HER911</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e784 class=n-a></a>HEK293T</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e788 class=n-a></a>Sf9 or Sf21</td></tr><tr><a name=d2623e793 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e795 class=n-a></a>Cells infected</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e798 class=n-a></a>Dividing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e801 class=n-a></a>Dividing or non-dividing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e804 class=n-a></a>Dividing or non-dividing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e807 class=n-a></a>Dividing or non-dividing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e811 class=n-a></a>Dividing or non-dividing</td></tr><tr><a name=d2623e815 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e817 class=n-a></a>Transduction efficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e820 class=n-a></a>Moderate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e823 class=n-a></a>High</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e826 class=n-a></a>Very high</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e829 class=n-a></a>High</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e833 class=n-a></a>High</td></tr><tr><a name=d2623e837 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e839 class=n-a></a>Transgene expression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e842 class=n-a></a>Stable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e845 class=n-a></a>Stable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e848 class=n-a></a>Transient</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e851 class=n-a></a>Transient</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e855 class=n-a></a>Transient</td></tr><tr><a name=d2623e859 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e861 class=n-a></a>Immune response</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e864 class=n-a></a>Moderate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e867 class=n-a></a>Low</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e870 class=n-a></a>High</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e873 class=n-a></a>Very low</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e877 class=n-a></a>Very low</td></tr><tr><a name=d2623e881 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e883 class=n-a></a>Toxicity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e886 class=n-a></a>High</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e889 class=n-a></a>Moderate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e892 class=n-a></a>High</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e895 class=n-a></a>Low</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e899 class=n-a></a>Low</td></tr><tr><a name=d2623e903 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e905 class=n-a></a>Random genome integration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e908 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e911 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e914 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e917 class=n-a></a>Generally no<br class=br>(recombinant AAV has a low<br class=br>frequency of host genome<br class=br>integration events)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e927 class=n-a></a>No</td></tr><tr><a name=d2623e932 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e934 class=n-a></a>Biosafety levels</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e937 class=n-a></a>BSL-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e940 class=n-a></a>BSL-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e943 class=n-a></a>BSL-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e946 class=n-a></a>BSL-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e950 class=n-a></a>BSL-1</td></tr><tr><a name=d2623e954 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e956 class=n-a></a>Common applications</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e959 class=n-a></a>Generating stable cell and<br class=br>gene transfer, cancer and<br class=br>stem cell research</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e966 class=n-a></a>Transduce difficult-to-<br class=br>transfect cell, genome-<br class=br>wide screens</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e973 class=n-a></a>Vaccine production, cancer<br class=br>immune therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e978 class=n-a></a>Gene delivery <i>in vivo</i>,<br class=br>optogenetics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e987 class=n-a></a>Recombinant proteins<br class=br>and vaccine production</td></tr><tr><a name=d2623e993 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e995 class=n-a></a>Clinical trials</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e998 class=n-a></a>Very popular</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1001 class=n-a></a>Very popular</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1004 class=n-a></a>Popular</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1007 class=n-a></a>Increasing popularity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1011 class=n-a></a>Growing interest</td></tr><tr><a name=d2623e1015 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1017 class=n-a></a>First <i>ex vivo</i> gene transfer<br class=br>clinical trial started (disease,<br class=br>ClinicalTrials.gov ID)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1027 class=n-a></a>1990<br class=br>(severe combined<br class=br>immunodeficiency,<br class=br>NCT00001255)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1036 class=n-a></a>2007<br class=br>(lymphoma, NCT00569985)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1041 class=n-a></a>2000<br class=br>(hepatocellular carcinoma,<br class=br>NCT00300521)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1048 class=n-a></a>None</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1052 class=n-a></a>None</td></tr><tr><a name=d2623e1056 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1058 class=n-a></a>First <i>in vivo</i> gene transfer<br class=br>clinical trial started (disease,<br class=br>ClinicalTrials.gov ID)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1068 class=n-a></a>None</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1071 class=n-a></a>2014<br class=br>(sickle cell anemia,<br class=br>NCT02186418)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1078 class=n-a></a>1993<br class=br>(cystic fibrosis, NCT00004779)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1083 class=n-a></a>1999<br class=br>(cystic fibrosis, NCT00004533)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1089 class=n-a></a>None</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d2623e1097 class=n-a></a><p id=d2623e1099> AcMNPV, autographa californica multicapsid nucleopolyhedrovirus; HIV, human immunodeficiency virus; ITR, inverted terminal repeat; LTR, long terminal repeat; Tn7, transposon 7.</p></div></div></div><p class="" id=d2623e1105>Here, we aim to review various AAV-CRISPR systems recently demonstrated in mice and to discuss how the combined use of tissue-specific minimal promoters, AAV serotypes, different routes of administration, and small Cas9 orthologues has enabled investigators to achieve maximal efficiency and specificity for <i>in vivo</i> genome editing. In addition, we discuss the clinical implications and potential strategies to overcome off-target effects, immunogenicity, and toxicity associated with CRISPR components and AAV delivery vehicles. Finally, we discuss the promises and hurdles associated with ongoing <i>ex vivo</i> gene therapy clinical trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2623e1117>AAV-CRISPR-based <i>in vivo</i> genome editing in mice</h2><p class="" id=d2623e1123>At least 33 published studies successfully used CRISPR/Cas9 alongside AAV vectors for <i>in vivo</i> genome editing in mice (<a href="#T2">Table 2</a>). The AAV-CRISPR system is particularly useful for editing disease-associated genes in the brain or central nervous system of mice because of the inability of most cationic nanocarriers to cross the blood-brain barrier, high transduction efficiency of AAV vectors in the brain, and non-dividing properties of neurons for long-term therapeutic effects. The AAV-CRISPR system has also been successfully used to restore the gene function in muscle-associated diseases such as Duchenne muscular dystrophy<sup><a href="#ref-54">54</a>–<a href="#ref-57">57</a></sup> and diseases associated with the eye<sup><a href="#ref-5">5</a>,<a href="#ref-58">58</a>–<a href="#ref-60">60</a></sup>, liver<sup><a href="#ref-4">4</a>,<a href="#ref-49">49</a>,<a href="#ref-61">61</a></sup>, heart<sup><a href="#ref-62">62</a>–<a href="#ref-64">64</a></sup>, and lung<sup><a href="#ref-65">65</a></sup>. This AAV-CRISPR-mediated gene editing in mice provided proof-of-principle studies for human disease modeling, gene therapy, or gene functional characterizations. We discuss recent developments and advancements in four critical aspects of the AAV-CRISPR system that have enabled efficient and precise <i>in vivo</i> genome editing in mice.</p><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. CRISPR/Cas9-based <i>in vivo</i> genome editing in mice with tissue-specific promoters and AAV variants.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2623e1188 class=n-a></a><thead><a name=d2623e1190 class=n-a></a><tr><a name=d2623e1192 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e1194 class=n-a></a>Target tissue in<br class=br>mouse<br class=br>(disease or<br class=br>phenotype)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e1203 class=n-a></a>Promoter –<br class=br>regulates CRISPR or<br class=br>reporter</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e1210 class=n-a></a>AAV<br class=br>serotype</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e1215 class=n-a></a>Route of<br class=br>administration<br class=br>(injection site)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e1222 class=n-a></a>Application<br class=br>(gene)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e1228 class=n-a></a>Phenotypic impact or<br class=br>therapeutic outcome</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e1233 class=n-a></a>Remark</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e1236 class=n-a></a>Reference</th></tr></thead><tbody><a name=d2623e1241 class=n-a></a><tr><a name=d2623e1243 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1245 class=n-a></a>Brain<br class=br>(study gene function)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1250 class=n-a></a>pMecp2 promoter - SpCas9<br class=br>hSyn1 promoter - GFP, KASH<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1257 class=n-a></a>AAV1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1260 class=n-a></a>Stereotactic injection<br class=br>(dentate gyrus)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1265 class=n-a></a>Gene knockout<br class=br>(<i>Mecp2</i>, <i>Dnmt1</i>,<br class=br><i>Dnmt3a</i>, and<br class=br><i>Dnmt3b</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1286 class=n-a></a>Impaired contextual memory<br class=br>and memory formation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1291 class=n-a></a>Can edit multiple<br class=br>genes simultaneously</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1296 class=n-a></a><a href="#ref-25">25</a></td></tr><tr><a name=d2623e1301 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1303 class=n-a></a>Brain<br class=br>(study brain circuit)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1308 class=n-a></a>hSyn1 promoter - SaCas9,<br class=br>Cre recombinase, GCaMP6f<br class=br>calcium sensor<br class=br>CAG promoter - tdTomato<br class=br>U6 promoter - Grna</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1319 class=n-a></a>AAV2-retro</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1322 class=n-a></a>Stereotactic injection<br class=br>(pontine nucleus,<br class=br>dorsal striatum)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1329 class=n-a></a>Gene knockout<br class=br>(<i>tdTomato</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1338 class=n-a></a>Enabled efficient mapping,<br class=br>monitoring, and manipulation<br class=br>of projection neurons</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1345 class=n-a></a>Modified AAV2<br class=br>capsid with a 7-mer<br class=br>peptide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1352 class=n-a></a><a href="#ref-68">68</a></td></tr><tr><a name=d2623e1357 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1359 class=n-a></a>Brain<br class=br>(Huntington disease)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1364 class=n-a></a>CMV promoter - SpCas9, eGFP<br class=br>U6 promoter - gRNA<br class=br>H1 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1371 class=n-a></a>AAV1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1374 class=n-a></a>Stereotactic injection<br class=br>(striata)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1379 class=n-a></a>SNP-<br class=br>dependent<br class=br>editing (<i>Htt</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1390 class=n-a></a>Reduced expression of mutant<br class=br><i>Htt</i> allele in mouse brain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1397 class=n-a></a>Use transgenic<br class=br>Huntington disease<br class=br>model</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1404 class=n-a></a><a href="#ref-76">76</a></td></tr><tr><a name=d2623e1409 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1411 class=n-a></a>Brain<br class=br>(schizophrenia)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1416 class=n-a></a>EF1a promoter - tdTomato<br class=br>CBh promoter - ScGFP<br class=br>hSyn1 promoter - ScGFP<br class=br>GFAP promoter - ScGFP<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1427 class=n-a></a>AAV2g9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1430 class=n-a></a>Stereotaxic injections<br class=br>(intracerebroventricular,<br class=br>cerebrospinal fluid)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1437 class=n-a></a>Gene deletion<br class=br>(<i>pre-miR137</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1446 class=n-a></a>Displayed preferential, robust,<br class=br>and widespread neuronal<br class=br>transduction within the brain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1453 class=n-a></a>Use Cas9 mice and<br class=br>an AAV chimeric<br class=br>derived from AAV2<br class=br>and AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1462 class=n-a></a><a href="#ref-80">80</a></td></tr><tr><a name=d2623e1467 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1469 class=n-a></a>Brain<br class=br>(inducible genome<br class=br>editing)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1476 class=n-a></a>Dox inducible Tight promoter<br class=br>- SpCas9<br class=br>TRE3G promoter - SpCas9<br class=br>pMecp2 - SpCas9<br class=br>CMV promoter - TetR, GFP,<br class=br>KASH<br class=br>H1/TO promoter - gRNA<br class=br>U6/TO promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1494 class=n-a></a>AAV-DJ<br class=br>AAV-DJ/8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1499 class=n-a></a>Stereotaxic injection<br class=br>(basal and lateral<br class=br>amygdala)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1506 class=n-a></a>Gene induction<br class=br>(<i>Tet2</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1515 class=n-a></a>Edited the genomes of<br class=br>neurons <i>in vivo</i> within the<br class=br>mouse brain in a Dox-<br class=br>dependent manner</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1527 class=n-a></a>Doxycycline-<br class=br>dependent gRNA<br class=br>expression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1534 class=n-a></a><a href="#ref-81">81</a></td></tr><tr><a name=d2623e1540 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1542 class=n-a></a>Brain<br class=br>(study gene<br class=br>function)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1549 class=n-a></a>CBh promoter - Cre<br class=br>recombinase<br class=br>hSyn1 promoter - GFP, KASH<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1558 class=n-a></a>AAV1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1561 class=n-a></a>Stereotactic injection<br class=br>(prefrontal cortex)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1566 class=n-a></a>Gene knock-in<br class=br>(<i>NeuN</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1575 class=n-a></a>NeuN protein depletion only in<br class=br>the injected region</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1580 class=n-a></a>Use Cre-dependent<br class=br>SpCas9 <i>Rosa26</i><br class=br>knock-in mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1589 class=n-a></a><a href="#ref-65">65</a></td></tr><tr><a name=d2623e1594 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1596 class=n-a></a>Brain<br class=br>(glioblastoma)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1601 class=n-a></a>U6 promoter - gRNA<br class=br>GFAP promoter - Cre<br class=br>recombinase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1608 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1611 class=n-a></a>Stereotactic injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1614 class=n-a></a>Gene mutation<br class=br>(<i>Trp53</i>, <i>Nf1</i>, or<br class=br><i>Rb1</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1630 class=n-a></a>Induced tumor formation<br class=br>that recapitulates human<br class=br>glioblastoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1637 class=n-a></a>Use LSL-Cas9 mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1640 class=n-a></a><a href="#ref-79">79</a></td></tr><tr><a name=d2623e1645 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1647 class=n-a></a>Brain<br class=br>(precise genome<br class=br>editing)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1654 class=n-a></a>EFS promoter - SpCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1659 class=n-a></a>AAV1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1662 class=n-a></a>Intraventricular and<br class=br>stereotactic injections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1667 class=n-a></a>Gene knock-in<br class=br>(<i>Camk2a</i>, <i>Erk2</i>,<br class=br><i>Actb</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1683 class=n-a></a>vSLENDR enabled efficient<br class=br>homology-directed repair<br class=br>in post-mitotic neurons in<br class=br>developing, adult, aged, and<br class=br>pathological brains</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1694 class=n-a></a>Use wild-type and<br class=br>Cas9 mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1699 class=n-a></a><a href="#ref-82">82</a></td></tr><tr><a name=d2623e1704 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1706 class=n-a></a>Brain<br class=br>(study gene function)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1711 class=n-a></a>U6 promoter - gRNA<br class=br>CBh promoter - Cre recombinase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1716 class=n-a></a>AAV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1719 class=n-a></a>Stereotactic injection<br class=br>(pyramidal neurons<br class=br>and microglia in<br class=br>hippocampus)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1728 class=n-a></a>Gene<br class=br>disruption<br class=br>(<i>Cnr2</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1739 class=n-a></a>Decreased contextual fear<br class=br>memory, enhanced spatial<br class=br>working memory</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1746 class=n-a></a>Use Camk2a-Cas9,<br class=br>Gad2-Cas9, and<br class=br>Cx3cr1-Cas9 mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1753 class=n-a></a><a href="#ref-83">83</a></td></tr><tr><a name=d2623e1758 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1760 class=n-a></a>Central nervous<br class=br>system<br class=br>(amyotrophic lateral<br class=br>sclerosis)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1769 class=n-a></a>CMV promoter - SpCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1774 class=n-a></a>scAAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1777 class=n-a></a>Intrathecal injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1780 class=n-a></a>Gene<br class=br>knockdown<br class=br>(<i>Igf1</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1791 class=n-a></a>Decreased D-amino acid<br class=br>oxidase and increased<br class=br>D-serine, and caspase9<br class=br>activation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1800 class=n-a></a>Use hSOD1G93A<br class=br>ALS mouse model</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1805 class=n-a></a><a href="#ref-84">84</a></td></tr><tr><a name=d2623e1810 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1812 class=n-a></a>Muscle<br class=br>(Duchenne muscular<br class=br>dystrophy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1819 class=n-a></a>CMV promoter - SaCas9<br class=br>EFS promoter - SaCas9<br class=br>CAGGS promoter - tdTomato<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1828 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1831 class=n-a></a>Intramuscular<br class=br>(tibialis anterior)<br class=br>and intraperitoneal<br class=br>(intraperitoneal space)<br class=br>injections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1842 class=n-a></a>Exon deletion<br class=br>(<i>Dmd</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1851 class=n-a></a>Partially recovered muscle<br class=br>functional deficiencies</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1856 class=n-a></a>Use mdx mouse<br class=br>model of DMD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1861 class=n-a></a><a href="#ref-54">54</a></td></tr><tr><a name=d2623e1867 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1869 class=n-a></a>Muscle<br class=br>(Duchenne muscular<br class=br>dystrophy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1876 class=n-a></a>CMV promoter - SaCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1881 class=n-a></a>AAV8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1884 class=n-a></a>Intramuscular (tibialis<br class=br>anterior), intraperitoneal<br class=br>(intraperitoneal space),<br class=br>and intravenous (tail<br class=br>vein) injections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1895 class=n-a></a>Exon deletion<br class=br>(<i>Dmd</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1904 class=n-a></a>Improved muscle function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1907 class=n-a></a>Use mdx mouse<br class=br>model of DMD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1912 class=n-a></a><a href="#ref-55">55</a></td></tr><tr><a name=d2623e1917 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1919 class=n-a></a>Muscle<br class=br>(Duchenne muscular<br class=br>dystrophy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1926 class=n-a></a>CMV promoter - SpCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1931 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1934 class=n-a></a>Intraperitoneal,<br class=br>intramuscular, and<br class=br>retro-orbital (venous<br class=br>sinus) injections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1943 class=n-a></a>Exon deletion<br class=br>(<i>Dmd</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1952 class=n-a></a>Enhanced skeletal muscle<br class=br>function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1957 class=n-a></a>Use mdx mouse<br class=br>model of DMD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1962 class=n-a></a><a href="#ref-56">56</a></td></tr><tr><a name=d2623e1967 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1969 class=n-a></a>Muscle<br class=br>(Duchenne muscular<br class=br>dystrophy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1976 class=n-a></a>CK8 promoter - SpCas9,<br class=br>SaCas9<br class=br>CMV promoter - mCherry<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1985 class=n-a></a>AAV6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1988 class=n-a></a>Intramuscular (tibialis<br class=br>anterior) and systemic<br class=br>(retro-orbital) injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e1995 class=n-a></a>Exon deletion<br class=br>and gene<br class=br>knock-in (<i>Dmd</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2006 class=n-a></a>Improved muscle function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2009 class=n-a></a>Use mdx4cv mouse<br class=br>model of DMD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2014 class=n-a></a><a href="#ref-57">57</a></td></tr><tr><a name=d2623e2019 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2021 class=n-a></a>Muscle<br class=br>(congenital<br class=br>muscular dystrophy<br class=br>type 1A)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2030 class=n-a></a>CMV promoter - SaCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2035 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2038 class=n-a></a>Intraperitoneal injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2041 class=n-a></a>Gene<br class=br>correction<br class=br>(<i>Lama2</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2052 class=n-a></a>Improved muscle histopathology<br class=br>and function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2057 class=n-a></a>Use dy2J/dy2J mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2060 class=n-a></a><a href="#ref-69">69</a></td></tr><tr><a name=d2623e2065 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2067 class=n-a></a>Retina<br class=br>(age-related macular<br class=br>degeneration)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2074 class=n-a></a>EFS promoter - CjCas9<br class=br>Spc512 promoter - CjCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2081 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2084 class=n-a></a>Intramuscular (tibialis<br class=br>anterior) and intravitreal<br class=br>injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2091 class=n-a></a>Gene knockout<br class=br>(<i>Rosa26</i>, <i>Vegfa</i>,<br class=br>and <i>Hif1a</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2108 class=n-a></a>Reduced the size of<br class=br>laser-induced choroidal<br class=br>neovascularization</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2115 class=n-a></a>Smallest Cas9<br class=br>orthologue (smaller<br class=br>than SaCas9)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2122 class=n-a></a><a href="#ref-5">5</a></td></tr><tr><a name=d2623e2127 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2129 class=n-a></a>Retina<br class=br>(Leber Congenital<br class=br>Amaurosis 10)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2136 class=n-a></a>CMV promoter - SpCas9,<br class=br>SaCas9<br class=br>hSyn1 promoter - eGFP<br class=br>GFAP promoter - eGFP<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2147 class=n-a></a>AAV5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2150 class=n-a></a>Subretinal injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2153 class=n-a></a>Gene deletion<br class=br>(<i>Cep290</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2162 class=n-a></a>Effectively removed intronic<br class=br>mutation in <i>Cep290</i> with<br class=br>minimized immune response</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2172 class=n-a></a>Use self-limiting<br class=br>CRISPR/Cas9 system</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2177 class=n-a></a><a href="#ref-58">58</a></td></tr><tr><a name=d2623e2183 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2185 class=n-a></a>Retina<br class=br>(retinal gene editing)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2190 class=n-a></a>pMecp2 promoter - SpCas9<br class=br>hSyn1 promoter - mCherry,<br class=br>KASH<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2199 class=n-a></a>AAV2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2202 class=n-a></a>Intravitreal (intraocular)<br class=br>injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2207 class=n-a></a>Gene knockout<br class=br>(<i>YFP</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2216 class=n-a></a>Effective gene knockout without<br class=br>affecting retinal function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2221 class=n-a></a>Use Thy1-YFP<br class=br>transgenic mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2226 class=n-a></a><a href="#ref-59">59</a></td></tr><tr><a name=d2623e2231 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2233 class=n-a></a>Retina<br class=br>(retinal degeneration)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2238 class=n-a></a>CMV promoter - SpCas9,<br class=br>tdTomato<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2245 class=n-a></a>AAV8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2248 class=n-a></a>Subretinal injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2251 class=n-a></a>Gene knockout<br class=br>(<i>Nrl</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2260 class=n-a></a>Prevented retinal degeneration,<br class=br>improved rod survival, and<br class=br>preserved cone function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2267 class=n-a></a>Use mouse models of<br class=br>retinal degeneration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2272 class=n-a></a><a href="#ref-60">60</a></td></tr><tr><a name=d2623e2277 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2279 class=n-a></a>Retina<br class=br>(angiogenesis)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2284 class=n-a></a>pICAM2 - SpCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2289 class=n-a></a>AAV1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2292 class=n-a></a>Intravitreal injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2295 class=n-a></a>Gene silencing<br class=br>(<i>VEGFR2</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2304 class=n-a></a>Abrogated angiogenesis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2307 class=n-a></a>Use mouse models<br class=br>of oxygen-induced<br class=br>retinopathy and<br class=br>laser-induced choroid<br class=br>neovascularization</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2318 class=n-a></a><a href="#ref-85">85</a></td></tr><tr><a name=d2623e2323 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2325 class=n-a></a>Liver<br class=br>(ornithine<br class=br>transcarbamylase)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2332 class=n-a></a>TBG promoter - SaCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2337 class=n-a></a>AAV8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2340 class=n-a></a>Intravenous injection<br class=br>(temporal vein)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2345 class=n-a></a>Gene knock-in<br class=br>(<i>Otc</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2354 class=n-a></a>Increased survival in mice<br class=br>challenged with a high-protein<br class=br>diet</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2361 class=n-a></a>Use adult OTC-<br class=br>deficient mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2366 class=n-a></a><a href="#ref-49">49</a></td></tr><tr><a name=d2623e2371 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2373 class=n-a></a>Liver<br class=br>(hereditary<br class=br>tyrosinemia)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2380 class=n-a></a>EF1a promoter - GFP<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2385 class=n-a></a>AAV8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2388 class=n-a></a>Systemic (tail vein)<br class=br>injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2393 class=n-a></a>Gene knock-in<br class=br>(<i>Fah</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2402 class=n-a></a>Rescued disease symptoms<br class=br>such as weight loss and liver<br class=br>damage</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2409 class=n-a></a>Use a mouse model<br class=br>of human hereditary<br class=br>tyrosinemia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2416 class=n-a></a><a href="#ref-61">61</a></td></tr><tr><a name=d2623e2421 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2423 class=n-a></a>Liver<br class=br>(total cholesterol)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2428 class=n-a></a>TBG promoter - SaCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2433 class=n-a></a>AAV8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2436 class=n-a></a>Systemic (tail vein)<br class=br>injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2441 class=n-a></a>Gene knockout<br class=br>(<i>Pcsk9</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2450 class=n-a></a>Reduced serum Pcsk9 and<br class=br>total cholesterol levels</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2455 class=n-a></a>Smaller Cas9<br class=br>orthologue than<br class=br>SpCas9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2462 class=n-a></a><a href="#ref-4">4</a></td></tr><tr><a name=d2623e2468 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2470 class=n-a></a>Liver<br class=br>(LDL cholesterol)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2475 class=n-a></a>CB promoter - EmGFP<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2480 class=n-a></a>AAV8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2483 class=n-a></a>Intraperitoneal injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2486 class=n-a></a>Gene knockout<br class=br>(<i>Ldlr</i>, <i>Apob</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2498 class=n-a></a>Resulted in severe<br class=br>hypercholesterolemia and<br class=br>atherosclerosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2505 class=n-a></a>Use Cas9 targeted<br class=br>transgenic mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2510 class=n-a></a><a href="#ref-77">77</a></td></tr><tr><a name=d2623e2515 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2517 class=n-a></a>Liver<br class=br>(hemophilia B)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2522 class=n-a></a>HCRhAATp promoter - SaCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2527 class=n-a></a>AAV8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2530 class=n-a></a>Systemic (tail vein)<br class=br>injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2535 class=n-a></a>Gene knock-in<br class=br>(<i>F9</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2544 class=n-a></a>Restored hemostasis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2547 class=n-a></a>Use <i>F9</i>-mutated mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2553 class=n-a></a><a href="#ref-71">71</a></td></tr><tr><a name=d2623e2558 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2560 class=n-a></a>Heart<br class=br>(PRKAG2 cardiac<br class=br>syndrome)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2567 class=n-a></a>CMV promoter - SpCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2572 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2575 class=n-a></a>Systemic injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2578 class=n-a></a>Gene knockout<br class=br>(<i>Prkag2</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2587 class=n-a></a>Restored the morphology<br class=br>and function of the heart after<br class=br>disrupting the mutant <i>Prkag2</i><br class=br>allele</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2598 class=n-a></a>Use H530R <i>Prkag2</i><br class=br>transgenic knock-in<br class=br>mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2607 class=n-a></a><a href="#ref-62">62</a></td></tr><tr><a name=d2623e2612 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2614 class=n-a></a>Heart<br class=br>(cardiac disease<br class=br>modeling)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2621 class=n-a></a>Myh6 promoter - SpCas9, GFP,<br class=br>TdTomato<br class=br>CMV promoter - ZsGreen<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2630 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2633 class=n-a></a>Intraperitoneal injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2636 class=n-a></a>Gene deletion<br class=br>(<i>Myh6</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2645 class=n-a></a>Displayed severe<br class=br>cardiomyopathy and loss of<br class=br>cardiac function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2652 class=n-a></a>Use postnatal<br class=br>cardiac-Cas9<br class=br>transgenic mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2659 class=n-a></a><a href="#ref-63">63</a></td></tr><tr><a name=d2623e2664 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2666 class=n-a></a>Heart<br class=br>(cardiac myocyte<br class=br>maturation)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2673 class=n-a></a>cTNT promoter - Cre<br class=br>recombinase<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2680 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2683 class=n-a></a>Subcutaneous injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2686 class=n-a></a>Gene knockout<br class=br>(<i>Jph2</i>, <i>Ryr2</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2698 class=n-a></a>Disrupted T-tubule structure<br class=br>and maturation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2703 class=n-a></a>Use RosaCas9GFP/<br class=br>Cas9GFP neonatal<br class=br>mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2710 class=n-a></a><a href="#ref-78">78</a></td></tr><tr><a name=d2623e2715 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2717 class=n-a></a>Heart<br class=br>(dystrophic<br class=br>cardiomyopathy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2724 class=n-a></a>CK7-miniCMV promoter - SaCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2729 class=n-a></a>AAV rh74</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2732 class=n-a></a>Systemic (retro-orbital,<br class=br>intraperitoneal) injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2737 class=n-a></a>Gene excision<br class=br>(<i>Dmd</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2746 class=n-a></a>Restored dystrophin expression<br class=br>and cardiac function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2751 class=n-a></a>Use mdx/Utr<sup>+</sup>/<sup>−</sup><br class=br>dystrophic mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2761 class=n-a></a><a href="#ref-70">70</a></td></tr><tr><a name=d2623e2767 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2769 class=n-a></a>Heart<br class=br>(cardiac gene<br class=br>function)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2776 class=n-a></a>CB promoter - SpCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2781 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2784 class=n-a></a>Intracardiac</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2787 class=n-a></a>Gene disruption<br class=br>(<i>Myh6</i>, <i>Sav1</i>,<br class=br>and <i>Tbx20</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2804 class=n-a></a>Resulted in mosaic pattern of<br class=br>gene disruption</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2809 class=n-a></a>Use Myh6-Cre<br class=br>transgenic mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2814 class=n-a></a><a href="#ref-64">64</a></td></tr><tr><a name=d2623e2819 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2821 class=n-a></a>Lung<br class=br>(lung<br class=br>adenocarcinoma)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2828 class=n-a></a>EFS promoter - Renilla<br class=br>luciferase, Cre recombinase<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2835 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2838 class=n-a></a>Intranasal (nostril) and<br class=br>intratracheal (trachea)<br class=br>injections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2845 class=n-a></a>Gene knock-in<br class=br>(<i>p53</i>, <i>Lkb1</i>,<br class=br>and <i>Kras</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2862 class=n-a></a>Led to macroscopic tumors<br class=br>of lung adenocarcinoma<br class=br>pathology</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2869 class=n-a></a>Use Cre-dependent<br class=br>SpCas9 <i>Rosa26</i><br class=br>knock-in mice</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2878 class=n-a></a><a href="#ref-65">65</a></td></tr><tr><a name=d2623e2883 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2885 class=n-a></a>Liver, heart, muscle<br class=br>(host immune<br class=br>response)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2892 class=n-a></a>SMVP promoter - SpCas9,<br class=br>SpCas9-VPR<br class=br>CASI promoter - SpCas9<br class=br>CAG promoter - tdTomato<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2903 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2906 class=n-a></a>Intramuscular and<br class=br>intraperitoneal<br class=br>injections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2913 class=n-a></a>Gene<br class=br>activation<br class=br>(<i>Mstn</i>, <i>Fst</i>, <i>Pd-l1</i>,<br class=br>and <i>Cd47</i>)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2936 class=n-a></a>Modest activation of <i>Pd-l1</i> and<br class=br><i>Cd47</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2945 class=n-a></a>Use AAV-split-Cas9<br class=br>system</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2950 class=n-a></a><a href="#ref-50">50</a></td></tr><tr><a name=d2623e2955 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2957 class=n-a></a>Circulating<br class=br>lymphocytes, spleen,<br class=br>liver, heart, lung,<br class=br>and kidney<br class=br>(eradication of HIV-1<br class=br>DNA)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2970 class=n-a></a>CMV promoter - SaCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2975 class=n-a></a>AAV9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2978 class=n-a></a>Systemic (tail vein)<br class=br>injection and retro-<br class=br>orbital inoculation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2985 class=n-a></a>Gene knockout<br class=br>(HIV-1 DNA)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2991 class=n-a></a>Eradication of HIV-1 DNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e2994 class=n-a></a>Use transgenic<br class=br>mice and rats<br class=br>encompassing the<br class=br>HIV-1 genome</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3003 class=n-a></a><a href="#ref-86">86</a></td></tr><tr><a name=d2623e3008 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3010 class=n-a></a>Spleen, lungs, heart,<br class=br>colon, and brain<br class=br>(HIV-1 proviral DNA<br class=br>excision)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3019 class=n-a></a>CMV promoter - SaCas9<br class=br>U6 promoter - gRNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3024 class=n-a></a>AAV-DJ/8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3027 class=n-a></a>Systemic (tail vein)<br class=br>injection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3032 class=n-a></a>Gene deletion<br class=br>(HIV-1 DNA)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3038 class=n-a></a>Induced efficient excision of<br class=br>HIV-1 proviral DNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3043 class=n-a></a>Use HIV-1 Tg26<br class=br>transgenic mice and<br class=br>humanized BLT mice<br class=br>with chronic HIV-1<br class=br>infection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3054 class=n-a></a><a href="#ref-72">72</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d2623e3063 class=n-a></a><p id=d2623e3065> AAV, adeno-associated virus; ALS, amyotrophic lateral sclerosis; <i>Apob</i>, apolipoprotein B; BLT, bone marrow/liver/thymus; CAG, a hybrid of CMV early enhancer and chicken beta-actin promoter; CAGGS, a hybrid of promoter composed of the CMV immediate-early enhancer, CBA promoter, and CBA intron 1/exon 1; <i>Camk2a</i>, calcium/calmodulin-dependent protein kinase II alpha; CASI, a hybrid of CMV enhancer and chicken β-actin promoter followed by a splice donor and splice acceptor; CB, chicken beta actin promoter; CBh, a hybrid form of the CBA promoter; <i>Cd47</i>, integrin-associated signal transducer; <i>Cep290</i>, centrosomal protein 290; CjCas9, <i>Campylobacter jejuni</i> Cas9; CK7, CK8, striated muscle-restricted promoter; CMV, cytomegalovirus; <i>Cnr2</i>, cannabinoid receptor 2; CRISPR, clustered regularly interspaced short palindromic repeat; cTNT, cardiac troponin T promoter; <i>Cx3cr1</i>, chemokine (C-X3-C motif) receptor 1; <i>Dmd</i>, Duchenne muscular dystrophy; <i>Dnmt</i>, DNA methyltransferase; EF1a, elongation factor-1 alpha; EFS, EF1a short; eGFP, enhanced green fluorescent protein; <i>Erk2</i>, mitogen-activated protein kinase 1; <i>F9</i>, coagulation factor IX; <i>Fah</i>, fumarylacetoacetate hydrolase; <i>Fst</i>, follistatin; <i>Gad2</i>, glutamic acid decarboxylase 2; GCaMP6f, green fluorescent calcium indicator; GFAP, glial fibrillary acidic protein; H1, human polymerase III RNA promoter; HCRhAATp, an enhancer element of the hepatic control region of the Apo E/C1 gene and the human anti-trypsin promoter; <i>Hif1a</i>, hypoxia-inducible factor 1 alpha; HIV, human immunodeficiency virus; hSyn1, human synapsin I; <i>Htt</i>, huntingtin; <i>Igf1</i>, insulin-like growth factor 1; <i>Jph2</i>, junctophilin-2; KASH, nuclear transmembrane domain; <i>Kras</i>, Kirsten rat sarcoma viral oncogene homolog; <i>Lama2</i>, laminin alpha 2; LDL, low-density lipoprotein; <i>Ldlr</i>, low-density lipoprotein receptor; <i>Lkb1</i>, serine/threonine kinase 11; mdx, dystrophin-deficient; <i>Mecp2</i>, methyl CpG binding protein 2; <i>Mstn</i>, myostatin; <i>Myh6</i>, myosin heavy polypeptide 6; <i>NeuN</i>, neuronal nuclear antigen; <i>Nf1</i>, neurofibromin 1; <i>Nrl</i>, neural retina-specific leucine zipper protein; <i>Otc</i>, ornithine transcarbamylase; <i>Pcsk9</i>, proprotein convertase subtilisin/kexin type 9; <i>Pd-l1</i>, programmed death-ligand 1; pICAM2, intercellular adhesion molecule 2 promoter; <i>Prkag2</i>, protein kinase AMP-activated non-catalytic subunit gamma 2; <i>p53</i>, transformation related protein 53; <i>Rb1</i>, RB transcriptional corepressor 1; <i>Roa26</i>, a safe harbor locus in mouse; <i>Ryr2</i>, ryanodine receptor 2; SaCas9, <i>Staphylococcus aureus</i> Cas9; <i>Sav1</i>, salvador family WW domain containing 1; SMVP, a hybrid of SV40 enhancer–CMV–promoter–chimeric intron; SNP, single-nucleotide polymorphism; SpCas9, <i>Streptococcus pyogenes</i> Cas9; Spc512, muscle-specific promoter; TBG, thyroxine binding globulin; <i>Tbx20</i>, T-box 20; <i>Tet2</i>, tet methylcytosine dioxygenase 2; <i>Thy1</i>, thymus cell antigen 1 theta; TRE3G, Tet-On 3G inducible promoter; TO, tetracycline operator; U6, human U6 small nuclear promoter; <i>Vegfa</i>, vascular endothelial growth factor A; <i>VEGFR2</i>, kinase insert domain protein receptor; VPR, a fusion of VP64–p65–Rta; vSLENDR, virus-mediated single-cell labeling of endogenous proteins via HDR; YFP, yellow fluorescent protein.</p></div></div></div><div class=section><a name=d2623e3210 class=n-a></a><h3 class=section-title>Small Cas9 orthologues</h3><p class="" id=d2623e3215>Even though the AAV vector is an extremely attractive delivery vehicle for CRISPR, its relatively small viral genome-packaging capacity has limited its use for delivering large transgenes. Using dual-vector AAV system or smaller Cas9 orthologues along with truncated regulatory elements (promoter and polyadenylation signal) has greatly circumvented the transgene packaging issue (<a href="#f1">Figure 1A</a>). Owing to a small AAV viral genome-packaging capacity (~4.8 kb), it has been technically challenging to co-package <i>Streptococcus pyogenes</i>-derived Cas9 (SpCas9) (4.1 kb) and multiple sgRNAs into all-in-one AAV vectors for multiplex genome editing. Recently, it has been demonstrated that when very small promoters were used (for example, miCMV promoter and H1 promoter to drive the expressions of SpCas9 and its gRNA, respectively), it was possible to package both SpCas9 and its gRNA into a single vector<sup><a href="#ref-32">32</a></sup>. However, the number of promoters that can be selected for tissue-specific transduction is limited. To circumvent this issue, the previously reported dual-vector system was adopted to express SpCas9 nuclease from one vector and to express its gRNAs together with a fluorescent reporter gene from another vector<sup><a href="#ref-25">25</a></sup>. Recently, St1Cas9 (~3.3 kb) from <i>Streptococcus thermophilus</i><sup><a href="#ref-66">66</a></sup> and a rationally designed truncated form of SpCas9<sup><a href="#ref-67">67</a></sup> were developed to fit SpCas9 and its gRNA into a single AAV construct. Unfortunately, St1Cas9 requires a more complex PAM sequence that limits the number of targetable loci<sup><a href="#ref-66">66</a></sup>, and truncated SpCas9 has a much lower efficiency than its wild-type counterpart<sup><a href="#ref-67">67</a></sup>.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12130/f71dec09-5425-4f40-b125-21c2e8e6dd5c_figure1.gif"><img alt="f71dec09-5425-4f40-b125-21c2e8e6dd5c_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12130/f71dec09-5425-4f40-b125-21c2e8e6dd5c_figure1.gif"></a><div class=caption><h3>Figure 1. CRISPR/Cas9-based <i>in vivo</i> genome editing by using small Cas9 orthologues, different routes of AAV administration, tissue-specific minimal promoters, and AAV serotypes.</h3><p id=d2623e3264>(<b>A</b>) AAV-CRISPR vectors. <i>Campylobacter jejuni</i>-derived Cas9 (CjCas9) is the smallest Cas9 orthologue (984 amino acids, 2.95 kb). <i>Staphylococcus aureus</i>-derived Cas9 (SaCas9) (1,053 amino acids, 3.16 kb) is smaller than the most widely used Cas9 derived from <i>Streptococcus pyogenes</i> (SpCas9) (1,368 amino acids, 4.10 kb). Owing to the large size of SpCas9, the SpCas9 gene and two gRNAs are packaged into two separate AAV vectors. The SpCas9-based dual-vector system enables one vector to express SpCas9 and another to express multiple gRNAs and a fluorescent reporter gene. Two gRNAs can be packaged with the SaCas9 into a single AAV vector if minimal promoter and polyadenylation signal are used. In the all-in-one vector system, CjCas9 enables packaging with two gRNAs and a fluorescent reporter gene, enhanced green fluorescent protein (<i>eGFP</i>), into a single AAV vector. (<b>B</b>) AAV serotypes for tissue-targeted delivery. (<b>C</b>) Tissue-specific minimal promoters for driving CRISPR expression. (<b>D</b>) Different routes of AAV administration into various tissues of a mouse. AAV, adeno-associated virus; CRISPR, clustered regulatory interspaced short palindromic repeat; gRNA, guide RNA.</p></div></div><p class="" id=d2623e3296>To overcome these drawbacks, other recently discovered small Cas9 orthologues, including <i>Staphylococcus aureus</i>-derived Cas9 (SaCas9, 3.16 kb)<sup><a href="#ref-4">4</a></sup> and <i>Campylobacter jejuni</i>-derived Cas9 (CjCas9, 2.95 kb)<sup><a href="#ref-5">5</a></sup>, have been used to package the Cas9 and its gRNA into a single AAV delivery vehicle for <i>in vivo</i> genome editing. To date, at least 11 independent <i>in vivo</i> studies have used the AAV-SaCas9 system to edit disease-associated genes in a variety of tissues, including brain<sup><a href="#ref-68">68</a></sup>, muscle<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a>,<a href="#ref-57">57</a>,<a href="#ref-69">69</a></sup>, retina<sup><a href="#ref-58">58</a></sup>, heart<sup><a href="#ref-70">70</a></sup>, and liver<sup><a href="#ref-4">4</a>,<a href="#ref-49">49</a>,<a href="#ref-71">71</a></sup>. More recently, the quadruplex gRNAs/SaCas9 vector consisting of SaCas9 and multiplex sgRNAs was successfully delivered using AAV-DJ/8 for <i>in vivo</i> excision of HIV-1 proviral DNA in various solid tissues/organs via a single intravenous injection in humanized bone marrow/liver/thymus (BLT) mice with chronic HIV-1 infection<sup><a href="#ref-72">72</a></sup>. In the all-in-one vector system, CjCas9 can be packaged with multiple gRNAs and even a fluorescent reporter gene into a single AAV vector<sup><a href="#ref-5">5</a></sup>. Even though CjCas9 represents the smallest Cas9 orthologue characterized to date, only one <i>in vivo</i> study has demonstrated the use of AAV vectors to deliver CjCas9 into the mouse’s retina for the treatment of age-related macular degeneration because of the recent development of CjCas9<sup><a href="#ref-5">5</a></sup>. Excitingly, AAV-CjCas9 offers the possibility of editing multiplex genes and tracking the expression of fluorescent reporter genes at high efficiency by simply introducing a single type of AAV vector into the mouse body. The CRISPR-mediated genome-editing specificities can be further improved by adopting truncated gRNAs<sup><a href="#ref-73">73</a></sup> and small chemical molecules to regulate Cas9 activity<sup><a href="#ref-74">74</a></sup> or to enhance double-stranded break-induced homologous recombination efficiency<sup><a href="#ref-75">75</a></sup> without sacrificing on-target genome-editing efficiencies.</p></div><div class=section><a name=d2623e3388 class=n-a></a><h3 class=section-title>Natural and engineered AAV serotypes</h3><p class="" id=d2623e3393>Multiple naturally occurring AAV serotypes have been harnessed to deliver the CRISPR/Cas9 complex into different tissues and organs in mice (<a href="#f1">Figure 1B</a>). AAV1 is particularly efficient to drive CRISPR transgene expression in the brain<sup><a href="#ref-25">25</a>,<a href="#ref-65">65</a>,<a href="#ref-76">76</a></sup>, whereas AAV8 appears well suited for the transduction of liver<sup><a href="#ref-4">4</a>,<a href="#ref-49">49</a>,<a href="#ref-61">61</a>,<a href="#ref-71">71</a>,<a href="#ref-77">77</a></sup> and muscle<sup><a href="#ref-55">55</a></sup> in mice. AAV9 has the general ability to transduce all major tissues, including muscle<sup><a href="#ref-54">54</a>,<a href="#ref-56">56</a>,<a href="#ref-69">69</a></sup>, retina<sup><a href="#ref-5">5</a></sup>, heart<sup><a href="#ref-62">62</a>–<a href="#ref-64">64</a>,<a href="#ref-78">78</a></sup>, and lung<sup><a href="#ref-65">65</a></sup>, in mice. Recently, the AAV9-CRISPR system has been successfully used to identify functional tumor suppressors in glioblastoma by performing high-throughput mutagenesis in the brain of conditional-Cas9 mice to recapitulate human glioblastoma<sup><a href="#ref-79">79</a></sup>. AAV2<sup><a href="#ref-59">59</a></sup> and AAV5<sup><a href="#ref-58">58</a></sup> have also been used to transduce retina, whereas AAV6<sup><a href="#ref-57">57</a></sup> enables CRISPR-mediated gene editing in muscle tissue.</p><p class="" id=d2623e3475>In order to alter tropism, reduce blockage by neutralizing antibodies, or enhance transduction efficiency, AAV capsids have been chemically or genetically modified to produce hybrid capsids by combining the properties of multiple serotypes, capsid shuffling, directed evolution, rational mutagenesis, or carrying peptide insertions that introduce the novel receptor-binding activity. AAV variants with engineered capsids (AAV2-retro, AAV2g9, AAV-DJ, and AAV-DJ/8) have been used to package CRISPR for transduction in the mouse brain. An <i>in vivo</i>-directed evolution-engineered AAV variant, rAAV2-retro, permits robust retrograde access to projection neurons in functionally connected and highly distributed networks with a high efficiency for neural circuit dissection and <i>in vivo</i> genome editing<sup><a href="#ref-68">68</a></sup>. An AAV chimera derived from AAV2 and AAV9, AAV2g9, enables preferential, robust, and widespread neuronal transduction within the mouse brain for CRISPR/Cas9-mediated gene deletion for the treatment of neurological disorders<sup><a href="#ref-80">80</a></sup>. To provide substantially higher infectivity rates across a broad range of tissues than any known native serotypes, the AAV-DJ was engineered by DNA family shuffling to create a hybrid capsid from eight different native serotypes<sup><a href="#ref-87">87</a></sup>. AAV-DJ/8 was created by introducing two point mutations in the heparin-binding domain of AAV-DJ to increase uptake in brain tissue <i>in vivo</i>, leading to a similar ability to infect heart and brain tissues with AAV8 and AAV9<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>. In fact, AAV-DJ/8 has been successfully used alongside the CRISPR/Cas9 system with doxycycline-dependent gRNA expression for inducible genome editing of neurons <i>in vivo</i> within the mouse brain<sup><a href="#ref-81">81</a></sup>. AAV-DJ/8 has also been successfully used to package and deliver the CRISPR/SaCas9 vectors for <i>in vivo</i> excision of HIV-1 proviral DNA in animal models<sup><a href="#ref-72">72</a></sup>.</p><p class="" id=d2623e3521>Recently, the capsids of AAV9, which is the most efficient native serotype characterized to date for <i>in vivo</i> transduction of the brain, have been further engineered for better performance in transductions and tissue targeting specificity. These include AAV-PHP.B (a chimeric AAV9 variant generated by inserting a 7-mer sequence, TLAVPFK, on AAV9 capsid)<sup><a href="#ref-13">13</a></sup>, AAV-AS (a chimeric AAV9 variant generated by inserting a poly-alanine peptide on AAV9 capsid)<sup><a href="#ref-14">14</a></sup>, and AAV9/3 (double tyrosine-mutant form of AAV9)<sup><a href="#ref-89">89</a></sup>, all of which were shown to be more efficient in transductions of the adult mouse central nervous system after intravenous injection compared with the wild-type AAV9. Furthermore, some of these engineered AAV capsids could de-target the native AAV tropism without affecting vector production, capsid assembly, infectivity, and gene transfer. Therefore, these novel engineered vectors offer promising options to package the CRISPR/Cas9 complex to efficiently edit disease-associated genes in the mouse brain or any other tissues. Additionally, self-complementary AAV9 (scAAV9) can be used to significantly decrease the time required for the onset of CRISPR expression in the central nervous system of mice<sup><a href="#ref-84">84</a></sup>. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant AAV vectors<sup><a href="#ref-31">31</a></sup>. The use of double-stranded self-complementary AAV (scAAV) has improved the transduction efficiencies by bypassing the second-strand synthesis step, but cloning capacity was further reduced to accommodate the complementary strand<sup><a href="#ref-90">90</a></sup>.</p></div><div class=section><a name=d2623e3554 class=n-a></a><h3 class=section-title>Tissue-specific minimal promoters</h3><p class="" id=d2623e3559>A tissue-specific promoter is important to ensure the expression of the CRISPR transgene in a tissue- or organ-specific manner. Various truncated or minimal tissue-specific promoters have been used to drive the expression of CRISPR in specific tissues upon injection of the AAV vectors into the mouse body (<a href="#f1">Figure 1C</a>). For example, the 235 base pair (bp) mouse pMecp2 (methyl CpG binding protein 2) and 485 bp human hSyn1 (human synapsin I) promoters have been used to efficiently and specifically drive the expression of CRISPR and other transgenes in the mouse brain<sup><a href="#ref-25">25</a></sup> and retina<sup><a href="#ref-59">59</a></sup>. A striated muscle-restricted promoter, CK8, enabled specific expression of SpCas9 and SaCas9 for gene editing in the muscle of the mdx mouse model of Duchenne muscular dystrophy upon intramuscular (tibialis anterior) or systemic (retro-orbital) injection of AAV6 vectors<sup><a href="#ref-57">57</a></sup>. The liver-specific TBG (thyroxine binding globulin)<sup><a href="#ref-4">4</a>,<a href="#ref-49">49</a></sup> and cardiac-specific Myh6 (myosin heavy polypeptide 6)<sup><a href="#ref-63">63</a></sup> promoters have been successfully used to drive the expression of CRISPR for <i>in vivo</i> genome editing in mouse liver and heart, respectively. More general promoters such as CMV (cytomegalovirus)<sup><a href="#ref-54">54</a>,<a href="#ref-58">58</a>,<a href="#ref-60">60</a>,<a href="#ref-62">62</a></sup> and EFS (elongation factor-1 alpha short)<sup><a href="#ref-5">5</a>,<a href="#ref-65">65</a></sup> can be used to express the CRISPR in multiple tissues, including muscle, retina, heart, and lung, for simultaneous gene editing of various tissues in mice. Compared with the CMV promoter, the elongation factor-1 alpha (EF1a) promoter tends to give more consistent and prolonged expression regardless of cell type or physiology<sup><a href="#ref-91">91</a>,<a href="#ref-92">92</a></sup>. EF1a is more stable in long-term culture because it maintains high transgene expression and stability and the copy number of episomal vectors<sup><a href="#ref-91">91</a></sup>. Thus, despite a stronger gene expression driven by the CMV promoter in many mammalian cell types, EF1a is preferred for efficient transgene expression in mouse embryonic stem cell lines<sup><a href="#ref-93">93</a></sup> and for engineering stable tumor cell lines<sup><a href="#ref-92">92</a></sup>. The library of minimal tissue-specific promoters alongside AAV vectors used for controlling the expression of CRISPR or other transgenes <i>in vivo</i> is expanding with the development of more tightly regulated synthetic hybrid promoters, such as widely used CAG, CAGGS, CASI, CBh, GFAP, TRE3G, SMVP, Spc512, H1/T0, CK7-miniCMV, pICAM2, HCRhAATp, and Tight promoters (<a href="#T2">Table 2</a>).</p><p class="" id=d2623e3638>Chimeric gRNA expression is frequently driven by an RNA polymerase III promoter, most often by the human U6 small nuclear (U6) promoter. The human U6 promoter has been shown to be more efficient than its murine homolog for short hairpin RNA (shRNA) expression in both human and murine cells<sup><a href="#ref-94">94</a></sup>. The human U6 promoter was also proven more efficient than the human H1 promoter in driving shRNA expression for the long-term inhibition of gene expression <i>in vitro</i> and <i>in vivo</i><sup><a href="#ref-95">95</a></sup>. However, the use of the U6 promoter to overexpress shRNAs <i>in vivo</i> can induce severe hepatotoxicity and inflammatory side effects due to abundant shRNA production<sup><a href="#ref-96">96</a></sup>. The weaker H1 promoter may offer a safer option in this case, but its therapeutic efficacy is dependent on the sequence of the shRNA<sup><a href="#ref-96">96</a></sup>. Some promoters require a particular nucleotide as the transcription start site (TSS) to initiate transcription. For instance, the human or mouse U6 promoters require a guanine nucleotide (G) at the 5′ end of the transcript for effective transcription<sup><a href="#ref-97">97</a></sup>. To use the U6 promoter for driving gRNA expression, the first nucleotide of the transcribed gRNA should be a G to maximize U6 promoter activity<sup><a href="#ref-97">97</a></sup>. If the G is absent at the TSS of the gRNA sequence, the human RNA polymerase III promoter H1 can be used to drive the expression of the gRNA<sup><a href="#ref-76">76</a></sup>. The use of H1 promoter-expressed gRNAs could enhance the versatility of the CRISPR technology by expanding the targetable genome<sup><a href="#ref-98">98</a></sup>. For multiplex CRISPR/Cas9-based genome editing such as large genomic DNA deletion or synergistically enhanced gene activation and repression, four independent polymerase III promoters (human U6 promoter, murine U6 promoter, 7SK, and H1) can be used to express four gRNAs in a single expression cassette<sup><a href="#ref-21">21</a></sup>. The use of distinct polymerase III promoters can avoid the problem of genetic recombination in a viral vector and the loss of the proximal gRNA due to identical DNA sequences of the promoters<sup><a href="#ref-99">99</a></sup>. The doxycycline-dependent promoters such as H1/TO and U6/TO can also be used for inducible <i>in vivo</i> genome editing by supplying animals with Dox-containing food to regulate the expression of the gRNA in a Dox-dependent manner<sup><a href="#ref-81">81</a></sup>. The introduction of Dox inhibits Tet repressor (TetR) binding and induces gRNA expression<sup><a href="#ref-81">81</a></sup>.</p></div><div class=section><a name=d2623e3703 class=n-a></a><h3 class=section-title>Local and global delivery of AAV vectors</h3><p class="" id=d2623e3708>The route of administration of AAV-CRISPR vectors into the mouse body also determines the efficacy and specificity of gene editing for <i>in vivo</i> therapeutics (<a href="#f1">Figure 1D</a>). Given the inability of the most native AAV serotypes (except for AAV9<sup><a href="#ref-100">100</a></sup>, AAVrh8<sup><a href="#ref-101">101</a></sup>, and AAVrh10<sup><a href="#ref-102">102</a></sup>) to cross the blood-brain barrier, stereotactic<sup><a href="#ref-25">25</a>,<a href="#ref-65">65</a>,<a href="#ref-76">76</a></sup> and intrathecal<sup><a href="#ref-84">84</a></sup> injections are still the preferred routes to systemic injection in order to introduce the AAV-CRISPR vectors into specific regions of the mouse brain or central nervous system for therapeutic gene editing. For the stereotactic injection, AAV-CRISPR vectors are intracranially injected into the brain by using a stereotaxic apparatus and the injection micropipette. In the intrathecal injection approach, AAV-CRISPR vectors are injected into the spinal canal or subarachnoid space to reach cerebrospinal fluid. For efficient therapeutic gene editing in the mouse muscle tissue, intramuscular (via tibialis anterior), intraperitoneal (via intraperitoneal space), or intravenous (via the tail vein, temporal vein, and retro-orbital) injections are the preferred methods to introduce AAV-CRISPR vectors, as have been demonstrated for the mdx mouse model of Duchenne muscular dystrophy<sup><a href="#ref-55">55</a>–<a href="#ref-57">57</a></sup>. Subretinal<sup><a href="#ref-58">58</a>,<a href="#ref-60">60</a></sup> or intravitreal<sup><a href="#ref-59">59</a>,<a href="#ref-85">85</a></sup> injections are used to deliver AAV-CRISPR vectors into the mouse retina for gene editing. As most of the AAV vectors will accumulate in the mouse liver tissue upon systemic injection, intravenous injection by tail vein or temporal vein can efficiently edit the genes associated with liver diseases<sup><a href="#ref-4">4</a>,<a href="#ref-49">49</a>,<a href="#ref-71">71</a></sup>. Systemic injection remains preferred to local injection in the liver tissue because the delivery is more uniform and the distribution of viral vectors is broader. It is also a good delivery mode for gene editing in multiple tissues, as it is almost non-invasive to the body. On the other hand, intracardiac<sup><a href="#ref-64">64</a></sup>, subcutaneous<sup><a href="#ref-78">78</a></sup>, intraperitoneal<sup><a href="#ref-63">63</a></sup>, or systemic<sup><a href="#ref-62">62</a>,<a href="#ref-70">70</a></sup> injection has been used to introduce AAV9 vectors carrying CRISPR transgene into the mouse heart for gene editing. Intranasal and intratracheal injections are used to locally deliver the AAV-CRISPR vehicles into the mouse lung tissue<sup><a href="#ref-65">65</a></sup>. Therefore, the selection of an effective route of injections is dependent on the target tissue, AAV serotypes, and tissue-specific promoters used.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2623e3803>CRISPR/Cas9-based human gene and cell therapies</h2><p class="" id=d2623e3806>In August 2016, the first human clinical trial using a CRISPR-based gene-editing technique was started for cancer immunotherapy of metastatic non-small cell lung cancer<sup><a href="#ref-103">103</a></sup>. Subsequently, 10 more early phase clinical trials are underway (ClinicalTrials.gov). One of these clinical trials has proceeded to phase 2 for the treatment of advanced esophageal cancer. Six of these early phase clinical trials are using the CRISPR/Cas9 system to create genetically altered immune cells, which are infused back into patients with an advanced stage of lung, bladder, prostate, renal, gastric, esophageal, or nasopharyngeal carcinoma or lymphoma to target and eradicate cancer cells (<a href="#T3">Table 3</a>). In general, the programmed cell death protein 1 gene (<i>PDCD1</i>) will be knocked out in autologous T cells. These engineered T cells then will be selected and expanded <i>ex vivo</i> before infusion back into the patients. PDCD1, more commonly known as PD-1, is an inhibitory cell surface receptor involved in the regulation of T-cell function during immune response and tolerance. Knockout of <i>PD-1</i> in T cells extracted from the patient’s blood could prevent cells’ immune response from switch-off after re-introduction of the gene-edited cells into the patient’s bloodstream and attack and defeat the cancer cells<sup><a href="#ref-104">104</a></sup>. In fact, antibodies (for example, nivolumab and pembrolizumab) that neutralize PD-1 with high response and low adverse effect rates have been successfully used for cancer immunotherapy in human clinical trials<sup><a href="#ref-105">105</a>,<a href="#ref-106">106</a></sup>. Gene editing is expected to inhibit PD-1 with a greater certainty, and by multiplying the cells in the laboratory, scientists can enhance the efficacy of triggering an immune response against tumors<sup><a href="#ref-104">104</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3>Table 3. Ongoing human clinical trials involving CRISPR/Cas9-based gene and cellular therapies.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2623e3852 class=n-a></a><thead><a name=d2623e3854 class=n-a></a><tr><a name=d2623e3856 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3858 class=n-a></a>Condition</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3861 class=n-a></a>Intervention</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3864 class=n-a></a>Phase</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3867 class=n-a></a>Type</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3870 class=n-a></a>Primary objective and study<br class=br>design</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3876 class=n-a></a>Principle</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3879 class=n-a></a>Start date</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3882 class=n-a></a>Finish date</th><th align=left colspan=1 rowspan=1 valign=top><a name=d2623e3885 class=n-a></a>ClinicalTrials.<br class=br>gov identifier</th></tr></thead><tbody><a name=d2623e3892 class=n-a></a><tr><a name=d2623e3894 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3896 class=n-a></a>Metastatic non-<br class=br>small cell lung<br class=br>cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3903 class=n-a></a>Biological: CRISPR/Cas9-<br class=br>mediated <i>PD-1</i> knockout<br class=br>T cells from autologous origin<br class=br>Drug: cyclophosphamide,<br class=br>interleukin-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3917 class=n-a></a>Phase 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3920 class=n-a></a> <i>Ex vivo</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3926 class=n-a></a>A dose-escalation study to<br class=br>evaluate the safety of <i>ex vivo</i><br class=br>knocked-out, expanded,<br class=br>and selected <i>PD-1</i> knockout<br class=br>engineered T cells that are<br class=br>infused back into the patient for<br class=br>the treatment of metastatic non-<br class=br>small cell lung cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3950 class=n-a></a>Target cancer<br class=br>cell</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3955 class=n-a></a>August 2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3958 class=n-a></a>April 2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3961 class=n-a></a>NCT02793856</td></tr><tr><a name=d2623e3965 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3967 class=n-a></a>Muscle-invasive<br class=br>bladder cancer<br class=br>stage IV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3974 class=n-a></a>Biological: CRISPR/Cas9-<br class=br>mediated <i>PD-1</i> knockout<br class=br>T cells from autologous origin<br class=br>Drug: cyclophosphamide,<br class=br>interleukin-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3988 class=n-a></a>Phase 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3991 class=n-a></a><i>Ex vivo</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e3995 class=n-a></a>A dose-escalation study of<br class=br><i>ex vivo</i> knocked-out, expanded,<br class=br>and selected <i>PD-1</i> knockout<br class=br>engineered T cells that are<br class=br>infused back into the patient for<br class=br>the treatment of muscle-invasive<br class=br>bladder cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4017 class=n-a></a>Target cancer<br class=br>cell</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4022 class=n-a></a>September<br class=br>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4027 class=n-a></a>September<br class=br>2019</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4032 class=n-a></a>NCT02863913</td></tr><tr><a name=d2623e4036 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4038 class=n-a></a>Hormone-refractory<br class=br>prostate cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4043 class=n-a></a>Biological: CRISPR/Cas9-<br class=br>mediated <i>PD-1</i> knockout<br class=br>T cells from autologous origin<br class=br>Drug: cyclophosphamide,<br class=br>interleukin-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4057 class=n-a></a>Phase 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4060 class=n-a></a> <i>Ex vivo</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4066 class=n-a></a>A dose-escalation study of<br class=br><i>ex vivo</i> knocked-out, expanded,<br class=br>and selected <i>PD-1</i> knockout<br class=br>engineered T cells that are<br class=br>infused back into the patient<br class=br>for the treatment of castration-<br class=br>resistant prostate cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4088 class=n-a></a>Target cancer<br class=br>cell</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4093 class=n-a></a>November<br class=br>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4098 class=n-a></a>December<br class=br>2020</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4103 class=n-a></a>NCT02867345</td></tr><tr><a name=d2623e4107 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4109 class=n-a></a>Metastatic renal<br class=br>cell carcinoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4114 class=n-a></a>Biological: CRISPR/Cas9-<br class=br>mediated <i>PD-1</i> knockout<br class=br>T cells from autologous origin<br class=br>Drug: cyclophosphamide,<br class=br>interleukin-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4128 class=n-a></a>Phase 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4131 class=n-a></a><i>Ex vivo</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4135 class=n-a></a>A dose-escalation study of<br class=br><i>ex vivo</i> knocked-out, expanded,<br class=br>and selected <i>PD-1</i> knockout<br class=br>engineered T cells that are<br class=br>infused back into the patient<br class=br>for the treatment of metastatic<br class=br>advanced renal cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4157 class=n-a></a>Target cancer<br class=br>cell</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4162 class=n-a></a>November<br class=br>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4167 class=n-a></a>November<br class=br>2020</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4172 class=n-a></a>NCT02867332</td></tr><tr><a name=d2623e4176 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4178 class=n-a></a>Advanced<br class=br>esophageal cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4183 class=n-a></a>Biological: CRISPR/Cas9-<br class=br>mediated <i>PD-1</i> knockout<br class=br>T cells from autologous origin<br class=br>Drug: cyclophosphamide,<br class=br>interleukin-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4197 class=n-a></a>Phase 2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4200 class=n-a></a><i>Ex vivo</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4204 class=n-a></a>Evaluate the safety of <i>ex vivo</i><br class=br>knocked-out, expanded, and<br class=br>selected <i>PD-1</i> knockout T cells<br class=br>that are infused back into the<br class=br>patient for the treatment of<br class=br>advanced esophageal cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4224 class=n-a></a>Target cancer<br class=br>cell</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4229 class=n-a></a>March 2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4232 class=n-a></a>December<br class=br>2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4237 class=n-a></a>NCT03081715</td></tr><tr><a name=d2623e4242 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4244 class=n-a></a>Gastric carcinoma<br class=br>stage IV,<br class=br>nasopharyngeal<br class=br>carcinoma stage IV,<br class=br>T-cell lymphoma<br class=br>stage IV, adult<br class=br>Hodgkin lymphoma<br class=br>stage IV, diffuse<br class=br>large B-cell<br class=br>lymphoma stage IV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4266 class=n-a></a>Biological: CRISPR/Cas9-<br class=br>mediated <i>PD-1</i> knockout<br class=br>T cells from autologous origin<br class=br>Drug: fludarabine,<br class=br>cyclophosphamide,<br class=br>interleukin-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4283 class=n-a></a>Phase 1/2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4286 class=n-a></a> <i>Ex vivo</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4292 class=n-a></a>Evaluate the safety and clinical<br class=br>response of cell therapy using<br class=br>CRISPR-Cas9-mediated <i>PD-1</i><br class=br>knockout EBV-CTL cells for the<br class=br>treatment of advanced-stage<br class=br>EBV-associated malignancies</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4308 class=n-a></a>Target EBV-<br class=br>associated<br class=br>cancer cell</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4315 class=n-a></a>April 2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4318 class=n-a></a>March 2022</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4321 class=n-a></a>NCT03044743</td></tr><tr><a name=d2623e4325 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4327 class=n-a></a>HIV-1-infection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4330 class=n-a></a>Biological: CRISPR/Cas9-<br class=br>mediated <i>CCR5</i> modified<br class=br>CD34<sup>+</sup> hematopoietic stem/<br class=br>progenitor cells from donors<br class=br>Drug: anti-retroviral therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4348 class=n-a></a>Phase 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4351 class=n-a></a><i>Ex vivo</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4356 class=n-a></a>Evaluate the safety and<br class=br>feasibility of allotransplantation<br class=br>with CRISPR/Cas9 <i>CCR5</i> gene<br class=br>modified CD34<sup>+</sup> hematopoietic<br class=br>stem/progenitor cells in<br class=br>HIV-infected patients with<br class=br>hematological malignances</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4379 class=n-a></a>Target CCR5-<br class=br>positive<br class=br>immune cell</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4386 class=n-a></a>May 2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4389 class=n-a></a>May 2021</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4392 class=n-a></a>NCT03164135</td></tr><tr><a name=d2623e4396 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4398 class=n-a></a>B-cell leukemia,<br class=br>B-cell lymphoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4403 class=n-a></a>Biological: gene-disrupted<br class=br>allogeneic CD19-directed<br class=br>BBζ CAR-T cells (termed<br class=br>UCART019) will be<br class=br>generated by combining the<br class=br>lentiviral delivery of CAR and<br class=br>CRISPR RNA electroporation<br class=br>to disrupt endogenous <i>TCR</i><br class=br>and <i>B2M</i> genes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4428 class=n-a></a>Phase 1/2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4431 class=n-a></a> <i>Ex vivo</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4437 class=n-a></a>Evaluate the feasibility, safety,<br class=br>and <i>in vivo</i> persistence of<br class=br>UCART019 adoptively transferred<br class=br>T cells in patients with relapsed<br class=br>or refractory CD19<sup>+</sup> leukemia and<br class=br>lymphoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4458 class=n-a></a>Target cancer<br class=br>cell</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4463 class=n-a></a>June 2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4466 class=n-a></a>May 2022</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4469 class=n-a></a>NCT03166878</td></tr><tr><a name=d2623e4473 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4475 class=n-a></a>Human<br class=br>papillomavirus-<br class=br>related malignant<br class=br>neoplasm</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4484 class=n-a></a>Biological: TALEN and<br class=br>CRISPR/Cas9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4489 class=n-a></a>Phase 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4492 class=n-a></a> <i>In vivo</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4498 class=n-a></a>An open-label and triple-cohort<br class=br>study to evaluate the safety and<br class=br>efficacy of TALEN and CRISPR/<br class=br>Cas9 plasmids for the treatment<br class=br>of HPV persistency and HPV-<br class=br>related cervical intraepithelial<br class=br>neoplasia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4515 class=n-a></a>Disrupt HPV<br class=br>E6/E7 DNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4520 class=n-a></a>January 2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4523 class=n-a></a>January<br class=br>2019</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4528 class=n-a></a>NCT03057912</td></tr><tr><a name=d2623e4532 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4534 class=n-a></a>Neurofibromatosis<br class=br>type 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4539 class=n-a></a>Biological: establish isogenic<br class=br><i>NF1</i> wild-type (<i>NF1</i><sup>+</sup>/<sup>+</sup>), <i>NF1</i><br class=br>heterozygous (<i>NF1</i><sup>+</sup>/<sup>−</sup>), and<br class=br><i>NF1</i> homozygous (<i>NF1</i><sup>−</sup>/<sup>−</sup>)<br class=br>patient-specific iPSC<br class=br>lines using CRISPR/Cas9<br class=br>technology</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4586 class=n-a></a>Phase 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4589 class=n-a></a> <i>Ex vivo</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4595 class=n-a></a>Establish an iPSC bank for disease<br class=br>phenotypic characterization,<br class=br>drug screening, and identification<br class=br>that can reverse or alleviate the<br class=br>disease phenotypes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4607 class=n-a></a>Collection of<br class=br>stem cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4612 class=n-a></a>November<br class=br>2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4617 class=n-a></a>June 2019</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4620 class=n-a></a>NCT03332030</td></tr><tr><a name=d2623e4624 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4626 class=n-a></a>Gastrointestinal<br class=br>infection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4631 class=n-a></a>Biological: knockout CRISPR<br class=br>and gain-of-function CRISPR<br class=br>SAM<br class=br>Procedure: duodenal biopsy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4640 class=n-a></a>Phase 1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4643 class=n-a></a> <i>Ex vivo</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4649 class=n-a></a>Identify and establish a list of<br class=br>host cellular proteins that mediate<br class=br>norovirus infection in a stem cell-<br class=br>derived human intestinal enteroid<br class=br>model</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4661 class=n-a></a>Genome-<br class=br>wide genetic<br class=br>screening</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4668 class=n-a></a>January 2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4671 class=n-a></a>December<br class=br>2020</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4676 class=n-a></a>NCT03342547</td></tr><tr><a name=d2623e4681 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4683 class=n-a></a>Sickle cell disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4686 class=n-a></a>Overall genetic literacy,<br class=br>CRISPR-specific literacy, and<br class=br>general attitudes and beliefs<br class=br>toward CRISPR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4695 class=n-a></a>Observational</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4698 class=n-a></a>Cross-<br class=br>sectional</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4703 class=n-a></a>Study the attitudes, beliefs, and<br class=br>opinions of those with SCD,<br class=br>parents of those with SCD, and<br class=br>providers on the use of CRISPR/<br class=br>Cas9 gene-editing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4715 class=n-a></a>–</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4718 class=n-a></a>October 2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4721 class=n-a></a>June 2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2623e4724 class=n-a></a>NCT03167450</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d2623e4732 class=n-a></a><p id=d2623e4734> Based on ClinicalTrials.gov database on human clinical trials performed in the US and worldwide. <i>B2M</i>, beta-2-microglobulin; CAR, chimeric antigen receptor; <i>CCR5</i>, C-C chemokine receptor type 5; CTL, cytotoxic T-lymphocyte; EBV, Epstein-Barr virus; HPV, human papillomavirus; iPSC, induced pluripotent stem cell; <i>NF1</i>, neurofibromatosis type 1; <i>PD-1</i>, programmed cell death protein 1 gene; SCD, sickle cell disease; TALEN, transcription activator-like effector nuclease; <i>TCR</i>, T-cell receptor.</p></div></div></div><p class="" id=d2623e4755>These interventional studies aimed to evaluate the clinical response, safety, and maximal tolerant dose of the CRISPR-mediated <i>PD-1</i> knockout T cells in treating advanced-stage malignancies upon being infused back into patients. An anti-cancer chemotherapy drug, cyclophosphamide, will be administered for a few days to modify the immune micro-environment before cell infusion or to deplete regulatory T cells (Tregs) before collecting peripheral blood. After cell infusion, the interleukin-2 cytokine that has both immune-modulating and anti-tumor properties will be administered to sustain the survival of infused T cells. For cancer immunotherapy of lymphoma or leukemia, an anti-metabolite anti-cancer chemotherapy drug, fludarabine, will be co-administered with the cyclophosphamide before cell infusion. Biomarkers and immunological markers will be closely monitored after cell infusion to determine whether the injections are causing any serious adverse effects and to evaluate whether the patients will receive benefits from the treatment.</p><p class="" id=d2623e4761>In another CRISPR/Cas9-based <i>ex vivo</i> gene therapy clinical trial, the CRISPR/Cas9 complex will be used to disrupt the C-C chemokine receptor type 5 (<i>CCR5</i>) gene in the CD34<sup>+</sup> hematopoietic stem or progenitor cells from donors (NCT03164135). Then, these <i>CCR5</i> modified CD34<sup>+</sup> cells from donors will be infused into the HIV-infected patients with AIDS and hematological malignancies. In principle, HIV-1 virus requires CCR5 receptor on the surface of host immune cells (for example, T cells) to infect the cell; hence, disrupting or blocking the CCR5 receptor may make the immune cell resistant to the virus infection. When the <i>CCR5</i>-modified immune cells from the donor are mixed inside the body with the CCR5-positive immune cells from HIV-infected patients, the HIV-1 virus will infect and kill the CCR5-positive immune cells and the CCR5-negative immune cells will survive and eventually take over the immune function. The primary objectives of this clinical trial are to determine the safety of the allotransplantation of these CD34<sup>+</sup> cells and to evaluate the resistance to the HIV-1 virus in HIV-infected patients after infusion of these CD34<sup>+</sup> cells. Prior to the cell infusion, the patients will be treated with anti-retroviral therapy to achieve undetectable HIV-1 virus in the peripheral blood. During the follow-up, HIV-1 viral load, CD4<sup>+</sup> T cells, and CCR5-negative cell counts in the peripheral blood will be monitored in HIV-infected patients.</p><p class="" id=d2623e4793>Another promising <i>ex vivo</i> gene therapy clinical trial is the combined use of CRISPR/Cas9 gene-editing technology and chimeric antigen receptor (CAR)-based cancer immunotherapy (NCT03166878). The CAR-expressed T cells can be engineered to recognize leukemia antigens such as CD19 on B cells for the treatment of relapsed or refractory B-cell malignancies. However, the cost and technical difficulties in the production and expansion of CAR-expressed T cells have hindered the wide application of personalized autologous CAR–T cell therapy. Thus, universal CAR–T cells derived from healthy unrelated donors are developed to overcome some of these drawbacks. To evade host-mediated immunity and deliver anti-leukemic effects without graft-versus-host disease in patients with relapsed or refractory B-cell malignancies, gene-disrupted allogeneic CD19-directed BBζ CAR–T cells (known as UCART019) are developed by combining the lentiviral delivery of CAR and CRISPR mRNA electroporation to disrupt both of the endogenous T-cell receptor (<i>TCR</i>) and beta-2 microglobulin (<i>B2M</i>) genes. The TCR and B2M play important roles in triggering the immune response; hence, disrupting both of these genes could minimize immunogenicity associated with allotransplantation. The primary goal of these allogeneic CD19 CAR–T cells is to evaluate the feasibility, safety, and <i>in vivo</i> persistence of UCART019 adoptively transferred T cells in patients with relapsed or refractory CD19<sup>+</sup> leukemia and lymphoma. The amount of UCART019 cells (engraftment), humoral host immunity, and anti-tumor response upon UCART019 cell infusions will be monitored.</p><p class="" id=d2623e4811>Owing to the tissue complexities in humans, toxicity concern, and potential complications such as host immune response following a high dose of AAV vectors used to achieve significant therapeutic efficacy<sup><a href="#ref-107">107</a></sup>, the AAV-CRISPR viral delivery system is restricted to <i>ex vivo</i> gene editing or genetic manipulation in animals. One of the promising strategies to overcome this issue was to mutagenize the surface-exposed tyrosine residues on the AAV capsid in order to avoid AAV degradation by the host cell proteasome machinery and to improve AAV intracellular trafficking to the nucleus, which can lead to high transduction efficiency at lower vector doses<sup><a href="#ref-107">107</a></sup>. The combined use of capsid-modified and genome-modified next-generation AAV vectors has allowed higher transduction efficiency and transgene expression at further reduced doses<sup><a href="#ref-108">108</a></sup>. To date, the AAV-CRISPR gene-editing system was tested in non-human animals only, but the first <i>in vivo</i> gene therapy using CRISPR/Cas9 technology will be carried out in human clinical trials soon. In January 2018, an open-label and triple-cohort study will be conducted to evaluate the safety of therapeutic doses and the dosing regimen of CRISPR/Cas9 plasmid to treat human papillomavirus (HPV) persistency and HPV-related cervical intraepithelial neoplasia. Given the important roles that E6 and E7 play in HPV-driven carcinogenesis, CRISPR/Cas9-mediated disruption of HPV16 and HPV18 E6/E7 DNA could be an attractive approach for therapeutic interventions by significantly downregulating the expression of E6/E7 in order to induce HPV-associated cell apoptosis and to inhibit cell growth.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2623e4835>Promises and hurdles associated with the AAV-CRISPR system for future clinical applications</h2><p class="" id=d2623e4838>An increasing number of studies in mice have clearly demonstrated that the combined use of tissue-specific minimal promoters, natural and engineered AAV serotypes, different routes of administration, and small Cas9 orthologues enables efficient packaging and precise delivery of AAV-CRISPR vectors for targeted <i>in vivo</i> genome editing in specific tissues with minimized side effects. Nevertheless, special considerations are required when selecting tissue-specific promoters, natural and engineered AAV serotypes, or routes of administration to avoid non-specific delivery and transgene expression of the AAV. In addition, the off-target effects, toxicity, and immunogenicity associated with CRISPR/Cas9 delivery remain to be fully resolved.</p><div class=section><a name=d2623e4844 class=n-a></a><h3 class=section-title>Non-specific delivery and transgene expression</h3><p class="" id=d2623e4849>Tissue-specific promoters and AAV serotypes might still be able to transduce and induce transgene expression in healthy tissues or other non-target organs if a strong promoter or a high dose of viral vectors is introduced into the body by intravenous injection. Despite a significant improvement in the efficiency and specificity of newly discovered natural and engineered AAV variants for systemic delivery in mice, the toxicity and side effects associated with the non-specific delivery of the transgenes to the non-target tissues and organs remain a concern<sup><a href="#ref-13">13</a>,<a href="#ref-89">89</a></sup>. It is easier to get delivery vehicles taken up by liver than other organs upon systemic injection. Therefore, it is more challenging to specifically target non-liver organs than liver via a systemic delivery approach. For instance, recently discovered synthetic vectors, AAV-PHP.B<sup><a href="#ref-13">13</a></sup> and tyrosine-mutant AAV<sup><a href="#ref-89">89</a></sup>, were found to transduce the adult mouse central nervous system more efficiently and widely than the natural AAV9 after intravenous injection. However, these synthetic vectors can also transduce the liver and other peripheral organs upon systemic delivery<sup><a href="#ref-13">13</a>,<a href="#ref-89">89</a></sup>. In this case, local injections such as stereotaxic injection into the brain can minimize the possible complications or adverse side effects associated with non-specific expression of CRISPR in healthy tissues or other non-target organs.</p></div><div class=section><a name=d2623e4875 class=n-a></a><h3 class=section-title>Off-target effects</h3><p class="" id=d2623e4880>Even though CRISPR/Cas9 predominantly recognizes the intended target sites, a series of high-throughput genome-wide methods such as multiplex Digenome-seq<sup><a href="#ref-109">109</a>,<a href="#ref-110">110</a></sup>, ChIP-seq<sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup>, GUIDE-seq<sup><a href="#ref-113">113</a></sup>, and whole-genome sequencing<sup><a href="#ref-114">114</a></sup> as well as targeted deep sequencing<sup><a href="#ref-112">112</a></sup>, Cas9 toxicity screens<sup><a href="#ref-115">115</a></sup>, and SITE-seq biochemical methods<sup><a href="#ref-116">116</a></sup> have revealed evidence of off-target effects due to target mismatch tolerance of CRISPR/Cas9. As inter-individual natural genetic variation can affect CRISPR/Cas9 specificity<sup><a href="#ref-117">117</a></sup>, a recently developed CIRCLE-seq approach could be used to identify genome-wide off-target mutations of CRISPR/Cas9 that are associated with cell type-specific single-nucleotide polymorphisms to provide personalized specificity profiles<sup><a href="#ref-118">118</a></sup>. Notably, given the same target sequence of gRNA, off-target sites of Cas9 before and after being fused to a catalytic enzyme (for example, cytidine deaminase base editor and chromatin modifiers) could be different; therefore, independent assessment of their genome-wide specificities is recommended<sup><a href="#ref-119">119</a></sup>. Imprecise repair of Cas9-induced DNA double-stranded breaks can give rise to deleterious structural chromosomal rearrangements such as deletions, inversions, and translocations, which in turn may activate oncogenes or cause genome instability<sup><a href="#ref-120">120</a></sup>. Hence, high-throughput screenings of CRISPR/Cas9 off-target activity and further improvement in the fidelity of CRISPR/Cas9 on-target activity are essential for safety in clinical gene transfer applications.<b></b> </p><p class="" id=d2623e4937>There are many ways to minimize CRISPR/Cas9 off-target effects in the human genome. For example, a recently developed RNA-targeting Cas9 (RCas9) system could avoid permanent off-target genetic lesions in DNA-mediated CRISPR-based therapeutics<sup><a href="#ref-121">121</a></sup>. The RCas9 system consists of a fusion of rationally truncated dCas9 protein and PilT N-terminus (PIN) domain that can be packaged into the AAV vector for eliminating toxic microsatellite repeat expansion RNA or reducing repetitive RNA level without targeting the DNA<sup><a href="#ref-121">121</a></sup>. With a similar strategy, systemic delivery of dCas9/gRNA by AAV9 significantly reduced pathological RNA foci, rescued chloride channel 1 protein expression, and decreased myotonia in myotonic dystrophy mice by impeding the transcription of expanded microsatellite repeats<sup><a href="#ref-122">122</a></sup>. Another way is to deliver purified Cas9 RNPs rather than plasmid expression vectors<sup><a href="#ref-10">10</a>,<a href="#ref-123">123</a></sup>. Despite some technical constraints in non-viral delivery methods for <i>in vivo</i> administration, the use of Cas9 RNPs can limit the duration of Cas9 expression and decrease the chance of Cas9 nuclease cleaving at non-specific sites in a genome because of the rapid clearance from the cell<sup><a href="#ref-10">10</a>,<a href="#ref-123">123</a></sup>. Complementing the CRISPR-based editing capability with conditional genetic manipulation tools such as photoactivatable Cas9<sup><a href="#ref-124">124</a>,<a href="#ref-125">125</a></sup>, chemical-inducible Cas9<sup><a href="#ref-126">126</a>,<a href="#ref-127">127</a></sup>, or multiple inputs logic gate genetic circuits<sup><a href="#ref-128">128</a>,<a href="#ref-129">129</a></sup> enables the precise spatial and temporal control of Cas9 activity inside the cell, which in turn leads to the reduction in off-target activity. Alternatively, a pair of Cas9 nickases<sup><a href="#ref-130">130</a>–<a href="#ref-132">132</a></sup>, dCas9-FokI<sup><a href="#ref-133">133</a></sup>, or high-fidelity Cas9 variants such as SpCas9-HF1<sup><a href="#ref-134">134</a></sup>, eSpCas9<sup><a href="#ref-135">135</a></sup>, and HypaCas9<sup><a href="#ref-136">136</a></sup> can be used to minimize undesired off-target mutagenesis.</p><p class="" id=d2623e5015>The use of a scarless genome-editing strategy for targeted point mutation knock-in can also minimize unwanted mutation formations to favor the desired clean base editing outcomes<sup><a href="#ref-137">137</a>,<a href="#ref-138">138</a></sup>. For a point mutation knock-in, the efficiency of precise sequence replacement by CRISPR-mediated homology-directed repair (HDR) could be significantly increased by using asymmetric donor DNA<sup><a href="#ref-139">139</a></sup>, HDR enhancer<sup><a href="#ref-140">140</a></sup>, or short ssDNA donor oligonucleotides as a donor template instead of long plasmid donor<sup><a href="#ref-139">139</a></sup> or by inhibiting non-homologous end joining (NHEJ) activity<sup><a href="#ref-141">141</a></sup>. Also, the artificial chimeric RNAs<sup><a href="#ref-142">142</a></sup>—truncated<sup><a href="#ref-73">73</a>,<a href="#ref-113">113</a></sup> and chemically modified<sup><a href="#ref-143">143</a></sup> gRNAs—were shown to have lower off-target activity than the original gRNAs. A number of bioinformatics analysis tools such as GuideScan<sup><a href="#ref-144">144</a></sup>, CRISPRdirect<sup><a href="#ref-145">145</a></sup>, and Cas-OFFinder<sup><a href="#ref-146">146</a></sup> permit the specific design of gRNAs to avoid binding at the non-intended target sites in the human genome. The specificity of the gRNA designed can be improved by selecting a target sequence with two Gs at the 5′ terminus<sup><a href="#ref-131">131</a></sup> and avoiding potential mismatches at the seed sequence or base-pairing adjacent to the PAM<sup><a href="#ref-147">147</a></sup>. Another innovative way to improve the specificity and reduce the toxicity of the CRISPR/Cas9 is co-delivery of DNA decoys or competitive inhibitor oligonucleotides bearing all possible off-target sequences that can sequester and prevent the CRISPR/Cas9 from binding to the off-target sites within a host genome. A similar concept has been successfully demonstrated to alleviate the off-target effects of RNA interference by using RNA decoys to reduce the sense strand activity of shRNAs<sup><a href="#ref-148">148</a></sup>, while artificial microRNA (miRNA) sponges have been used to inhibit miRNA function and its ability to regulate natural mRNAs<sup><a href="#ref-149">149</a></sup>. In addition, a recently developed miRNA-responsive CRISPR/Cas9 switch could be useful for cell type-specific genome editing by sensing endogenous miRNA activities<sup><a href="#ref-150">150</a></sup>.</p></div><div class=section><a name=d2623e5091 class=n-a></a><h3 class=section-title>Immunogenicity</h3><p class="" id=d2623e5096>Owing to the exogenous nature of AAV and CRISPR components, host immune responses can attenuate therapeutic effects and cause side effects. Thus, the toxicity and immunogenicity associated with AAV and CRISPR components should be circumvented for safer and higher efficacy in clinical gene therapy applications. Even though the AAV generally elicits a very mild immune response and does not induce extensive cellular damage <i>in vivo</i>, certain AAV serotypes such as AAV9 may evoke humoral immune responses, as indicated by the presence of capsid-specific antibodies<sup><a href="#ref-50">50</a></sup>. While transient immunosuppression is one of the possible ways to mitigate the host immune response following the delivery of AAV vectors<sup><a href="#ref-151">151</a></sup>, it is not feasible for long-term therapeutic treatments of chronic diseases and is prone to adverse complications such as infections and malignancies. Empty capsid mutants can be used as decoys to overcome pre-existing humoral immunity by adsorbing antibodies in the bloodstream upon systemic delivery of both empty and functional AAVs<sup><a href="#ref-152">152</a></sup>. Alternatively, the AAV capsids can be genetically engineered or mutated to reduce the binding affinity and the neutralizing effects of AAV antibodies<sup><a href="#ref-15">15</a>,<a href="#ref-153">153</a>–<a href="#ref-155">155</a></sup>. In addition to AAVs, the presence of Cas9-specific antibodies in Cas9-exposed animals indicated that Cas9 could evoke deleterious cellular and humoral immune responses <i>in vivo</i><sup><a href="#ref-50">50</a></sup>. Expression of Cas9 <i>in vivo</i> could affect the transcription of the genes associated with the immunological processes. This in turn may destabilize the host immune system, elicit significant cellular infiltration or expansion, and induce enlargement of the draining lymph nodes with increased immune cell counts<sup><a href="#ref-50">50</a></sup>. The Cas9-responsive T-cell clonotype described previously could serve as a distinctive biomarker to assess Cas9-specific immunity before clinical implementation of the CRISPR system<sup><a href="#ref-50">50</a></sup>. To minimize the immune response due to prolonged expression of Cas9, conditional genome editing with the self-limiting CRISPR/Cas9 system<sup><a href="#ref-58">58</a></sup> or light-inducible<sup><a href="#ref-124">124</a>,<a href="#ref-125">125</a></sup> or chemical-inducible<sup><a href="#ref-126">126</a>,<a href="#ref-127">127</a></sup> Cas9 can be used to minimize the duration of Cas9 expression in the body.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2623e5165>Conclusions and perspectives</h2><p class="" id=d2623e5168>The AAV-CRISPR system holds enormous translational potential to develop curative therapeutic options for patients with severe and life-threatening genetic diseases by permanently editing disease-causing or risk genes in the human body. The delivery, efficacy, and safety issues in treating complex heritable and somatic disorders have to be fully resolved to fulfill this promise. Thus far, the <i>ex vivo</i> approach has been adopted to overcome the technical challenges associated with the <i>in vivo</i> delivery of the AAV-CRISPR viral vectors in humans. The <i>ex vivo</i> gene-editing approach is commonly used for the therapeutic treatment of blood disorders, cancers, and immune-related diseases. In the near future, <i>in vivo</i> genome editing is expected to offer better avenues to treat a wide range of human hereditary diseases in adults. <i>In vivo</i> gene therapy in humans provides several advantages over the <i>ex vivo</i> approach, and sometimes a combination of the two is necessary to achieve a good therapeutic outcome. For example, <i>in vivo</i> photoreceptor cell rescue can be used to halt retinal degeneration to preserve existing vision, while <i>ex vivo</i> photoreceptor cell replacement can be used to restore lost vision in patients with retinal dystrophy<sup><a href="#ref-156">156</a></sup>. After <i>in vivo</i> photoreceptor cell rescue, the retinal environment may become more permissive for transplanted photo-receptor survival and <i>de novo</i> synaptogenesis via the <i>ex vivo</i> approach<sup><a href="#ref-156">156</a></sup>.</p><p class="" id=d2623e5214>The AAV vector already has a long history of success in clinical trials <i>in vivo</i>, but owing to the relatively recent arrival of CRISPR technology, the AAV-CRISPR system has yet to be tested <i>in vivo</i> for human gene therapy trials. Nevertheless, three ongoing human clinical trials (NCT03041324, NCT02702115, and NCT02695160) have used AAV vectors to deliver zinc finger nucleases, an earlier and well-established gene-editing tool, to the liver tissue for the treatment of hemophilia B and mucopolysaccharidosis. Similarly, the AAV vectors may be used for CRISPR delivery for human clinical trials in the future. Excitingly, the first <i>in vivo</i> human gene therapy trials using CRISPR/Cas9 plasmid administration to treat human HPV-related malignant neoplasms will be initiated in January 2018 (NCT03057912).</p><p class="" id=d2623e5226>Although it is more feasible to deliver the transgene <i>ex vivo</i> than <i>in vivo</i>, the <i>in vivo</i> approach eliminates the need for cell transplants. Therefore, <i>in vivo</i> therapy can avoid potential graft-versus-host disease and immunosuppression-related complications such as infections and malignancies, as seen in cellular therapy. Recently, various genetically engineered AAV variants or structure-guided derivations of AAV mutants have been developed to significantly improve the efficiency and specificity for <i>in vivo</i> delivery<sup><a href="#ref-157">157</a></sup>. Compared with existing AAV serotypes, these newly engineered AAV capsids enabled higher transduction efficiency at a targeted tissue by altering the native tropism of the AAV capsid<sup><a href="#ref-13">13</a>–<a href="#ref-15">15</a>,<a href="#ref-158">158</a></sup> and had low immunogenicity by evading pre-existing anti-AAV capsid neutralizing antibodies in the human body<sup><a href="#ref-159">159</a>,<a href="#ref-160">160</a></sup>. Given the encouraging results obtained with the next-generation synthetic AAV capsids in animals, this synthetic AAV vector may also be used to deliver CRISPR/Cas9 transgene in humans for <i>in vivo</i> genome editing in the near future. Further improvement in the performance of engineered AAV variants and CRISPR components is necessary to realize the full potential of the AAV-CRISPR system for <i>in vivo</i> genome editing.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d2623e1 class=n-a></a><h2 class=main-title id=d3092>Competing interests</h2><p class=metadata-entry><a name=d2623e140 class=n-a></a><p id=d2623e141> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d2623e1 class=n-a></a><h2 class=main-title id=d3094>Grant information</h2><p>This work was funded by National Institutes of Health grants AG017242, GM104459, and CA180126 (to Yousin Suh).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript</i>.</p></div><div class=back-section><a name=d2623e5276 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d3675>References</h2><div class="section ref-list"><a name=d2623e5276 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d2623e5283 class=n-a></a>Lau CH, Suh Y: Genome and Epigenome Editing in Mechanistic Studies of Human Aging and Aging-Related Disease. <i>Gerontology.</i> 2017; <b>63</b>(2): 103–17. <a target=xrefwindow id=d2623e5291 href="http://www.ncbi.nlm.nih.gov/pubmed/27974723">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5294 href="http://dx.doi.org/10.1159/000452972">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5297 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5310972">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d2623e5306 class=n-a></a>Barrangou R, Doudna JA: Applications of CRISPR technologies in research and beyond. <i>Nat Biotechnol.</i> 2016; <b>34</b>(9): 933–41. <a target=xrefwindow id=d2623e5314 href="http://www.ncbi.nlm.nih.gov/pubmed/27606440">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5317 href="http://dx.doi.org/10.1038/nbt.3659">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717969062"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e5326 class=n-a></a>Cong L, Ran FA, Cox D, <i> et al.</i>: Multiplex genome engineering using CRISPR/Cas systems. <i>Science.</i> 2013; <b>339</b>(6121): 819–23. <a target=xrefwindow id=d2623e5337 href="http://www.ncbi.nlm.nih.gov/pubmed/23287718">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5340 href="http://dx.doi.org/10.1126/science.1231143">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5344 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3795411">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717969062">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d2623e5357 class=n-a></a>Ran FA, Cong L, Yan WX, <i> et al.</i>: <i>In vivo</i> genome editing using <i>Staphylococcus aureus</i> Cas9. <i>Nature.</i> 2015; <b>520</b>(7546): 186–91. <a target=xrefwindow id=d2623e5375 href="http://www.ncbi.nlm.nih.gov/pubmed/25830891">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5378 href="http://dx.doi.org/10.1038/nature14299">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5381 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4393360">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d2623e5390 class=n-a></a>Kim E, Koo T, Park SW, <i> et al.</i>: <i>In vivo</i> genome editing with a small Cas9 orthologue derived from <i>Campylobacter jejuni</i>. <i>Nat Commun.</i> 2017; <b>8</b>: 14500. <a target=xrefwindow id=d2623e5408 href="http://www.ncbi.nlm.nih.gov/pubmed/28220790">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5411 href="http://dx.doi.org/10.1038/ncomms14500">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5414 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5473640">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726984195"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e5424 class=n-a></a>Komor AC, Badran AH, Liu DR: CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. <i>Cell.</i> 2017; <b>168</b>(1–2): 20–36. <a target=xrefwindow id=d2623e5432 href="http://www.ncbi.nlm.nih.gov/pubmed/27866654">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5435 href="http://dx.doi.org/10.1016/j.cell.2016.10.044">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5438 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5235943">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726984195">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d2623e5451 class=n-a></a>Xiong X, Chen M, Lim WA, <i> et al.</i>: CRISPR/Cas9 for Human Genome Engineering and Disease Research. <i>Annu Rev Genomics Hum Genet.</i> 2016; <b>17</b>: 131–54. <a target=xrefwindow id=d2623e5462 href="http://www.ncbi.nlm.nih.gov/pubmed/27216776">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5465 href="http://dx.doi.org/10.1146/annurev-genom-083115-022258">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d2623e5474 class=n-a></a>Kouranova E, Forbes K, Zhao G, <i> et al.</i>: CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein into Cultured Cells and Single-Cell Embryos. <i>Hum Gene Ther.</i> 2016; <b>27</b>(6): 464–75. <a target=xrefwindow id=d2623e5485 href="http://www.ncbi.nlm.nih.gov/pubmed/27094534">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5488 href="http://dx.doi.org/10.1089/hum.2016.009">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5492 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4931306">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d2623e5501 class=n-a></a>Liang X, Potter J, Kumar S, <i> et al.</i>: Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. <i>J Biotechnol.</i> 2015; <b>208</b>: 44–53. <a target=xrefwindow id=d2623e5512 href="http://www.ncbi.nlm.nih.gov/pubmed/26003884">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5515 href="http://dx.doi.org/10.1016/j.jbiotec.2015.04.024">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d2623e5524 class=n-a></a>Kim S, Kim D, Cho SW, <i> et al.</i>: Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. <i>Genome Res.</i> 2014; <b>24</b>(6): 1012–9. <a target=xrefwindow id=d2623e5535 href="http://www.ncbi.nlm.nih.gov/pubmed/24696461">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5538 href="http://dx.doi.org/10.1101/gr.171322.113">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5542 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4032847">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d2623e5551 class=n-a></a>Fornito A, Zalesky A, Breakspear M: The connectomics of brain disorders. <i>Nat Rev Neurosci.</i> 2015; <b>16</b>(3): 159–72. <a target=xrefwindow id=d2623e5559 href="http://www.ncbi.nlm.nih.gov/pubmed/25697159">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5562 href="http://dx.doi.org/10.1038/nrn3901">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d2623e5572 class=n-a></a>Staahl BT, Benekareddy M, Coulon-Bainier C, <i> et al.</i>: Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. <i>Nat Biotechnol.</i> 2017; <b>35</b>(5): 431–4. <a target=xrefwindow id=d2623e5583 href="http://www.ncbi.nlm.nih.gov/pubmed/28191903">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5586 href="http://dx.doi.org/10.1038/nbt.3806">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726112855"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e5595 class=n-a></a>Deverman BE, Pravdo PL, Simpson BP, <i> et al.</i>: Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. <i>Nat Biotechnol.</i> 2016; <b>34</b>(2): 204–9. <a target=xrefwindow id=d2623e5606 href="http://www.ncbi.nlm.nih.gov/pubmed/26829320">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5609 href="http://dx.doi.org/10.1038/nbt.3440">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5613 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5088052">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726112855">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d2623e5626 class=n-a></a>Choudhury SR, Harris AF, Cabral DJ, <i> et al.</i>: Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector. <i>Mol Ther.</i> 2016; <b>24</b>(4): 726–35. <a target=xrefwindow id=d2623e5637 href="http://www.ncbi.nlm.nih.gov/pubmed/26708003">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5640 href="http://dx.doi.org/10.1038/mt.2015.231">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5644 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4886933">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d2623e5653 class=n-a></a>Choudhury SR, Fitzpatrick Z, Harris AF, <i> et al.</i>: <i>In vivo</i> Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. <i>Mol Ther.</i> 2016; <b>24</b>(7): 1247–57. <a target=xrefwindow id=d2623e5667 href="http://www.ncbi.nlm.nih.gov/pubmed/27117222">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5671 href="http://dx.doi.org/10.1038/mt.2016.84">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5674 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5088762">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d2623e5683 class=n-a></a>Yin H, Kauffman KJ, Anderson DG: Delivery technologies for genome editing. <i>Nat Rev Drug Discov.</i> 2017; <b>16</b>(6): 387–99. <a target=xrefwindow id=d2623e5691 href="http://www.ncbi.nlm.nih.gov/pubmed/28337020">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5694 href="http://dx.doi.org/10.1038/nrd.2016.280">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d2623e5703 class=n-a></a>Song M: The CRISPR/Cas9 system: Their delivery, <i>in vivo</i> and <i>ex vivo</i> applications and clinical development by startups. <i>Biotechnol Prog.</i> 2017; <b>33</b>(4): 1035–45. <a target=xrefwindow id=d2623e5717 href="http://www.ncbi.nlm.nih.gov/pubmed/28440027">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5721 href="http://dx.doi.org/10.1002/btpr.2484">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d2623e5731 class=n-a></a>He ZY, Men K, Qin Z, <i> et al.</i>: Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. <i>Sci China Life Sci.</i> 2017; <b>60</b>(5): 458–67. <a target=xrefwindow id=d2623e5742 href="http://www.ncbi.nlm.nih.gov/pubmed/28527117">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5745 href="http://dx.doi.org/10.1007/s11427-017-9033-0">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d2623e5754 class=n-a></a>Williams MR, Fricano-Kugler CJ, Getz SA, <i> et al.</i>: A Retroviral CRISPR-Cas9 System for Cellular Autism-Associated Phenotype Discovery in Developing Neurons. <i>Sci Rep.</i> 2016; <b>6</b>: 25611. <a target=xrefwindow id=d2623e5765 href="http://www.ncbi.nlm.nih.gov/pubmed/27161796">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5768 href="http://dx.doi.org/10.1038/srep25611">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5772 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4861960">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718276719"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e5781 class=n-a></a>Koike-Yusa H, Li Y, Tan EP, <i> et al.</i>: Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. <i>Nat Biotechnol.</i> 2014; <b>32</b>(3): 267–73. <a target=xrefwindow id=d2623e5792 href="http://www.ncbi.nlm.nih.gov/pubmed/24535568">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5795 href="http://dx.doi.org/10.1038/nbt.2800">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718276719">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d2623e5808 class=n-a></a>Kabadi AM, Ousterout DG, Hilton IB, <i> et al.</i>: Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. <i>Nucleic Acids Res.</i> 2014; <b>42</b>(19): e147. <a target=xrefwindow id=d2623e5819 href="http://www.ncbi.nlm.nih.gov/pubmed/25122746">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5822 href="http://dx.doi.org/10.1093/nar/gku749">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5826 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4231726">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d2623e5835 class=n-a></a>Wang D, Mou H, Li S, <i> et al.</i>: Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. <i>Hum Gene Ther.</i> 2015; <b>26</b>(7): 432–42. <a target=xrefwindow id=d2623e5846 href="http://www.ncbi.nlm.nih.gov/pubmed/26086867">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5849 href="http://dx.doi.org/10.1089/hum.2015.087">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5853 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4509492">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d2623e5862 class=n-a></a>Cheng R, Peng J, Yan Y, <i> et al.</i>: Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9. <i>FEBS Lett.</i> 2014; <b>588</b>(21): 3954–8. <a target=xrefwindow id=d2623e5873 href="http://www.ncbi.nlm.nih.gov/pubmed/25241167">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5876 href="http://dx.doi.org/10.1016/j.febslet.2014.09.008">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d2623e5886 class=n-a></a>Schmidt F, Grimm D: CRISPR genome engineering and viral gene delivery: a case of mutual attraction. <i>Biotechnol J.</i> 2015; <b>10</b>(2): 258–72. <a target=xrefwindow id=d2623e5894 href="http://www.ncbi.nlm.nih.gov/pubmed/25663455">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5897 href="http://dx.doi.org/10.1002/biot.201400529">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d2623e5906 class=n-a></a>Swiech L, Heidenreich M, Banerjee A, <i> et al.</i>: <i>In vivo</i> interrogation of gene function in the mammalian brain using CRISPR-Cas9. <i>Nat Biotechnol.</i> 2015; <b>33</b>(1): 102–6. <a target=xrefwindow id=d2623e5920 href="http://www.ncbi.nlm.nih.gov/pubmed/25326897">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5924 href="http://dx.doi.org/10.1038/nbt.3055">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5927 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4492112">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d2623e5936 class=n-a></a>Mansouri M, Ehsaei Z, Taylor V, <i> et al.</i>: Baculovirus-based genome editing in primary cells. <i>Plasmid.</i> 2017; <b>90</b>: 5–9. <a target=xrefwindow id=d2623e5947 href="http://www.ncbi.nlm.nih.gov/pubmed/28119062">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5950 href="http://dx.doi.org/10.1016/j.plasmid.2017.01.003">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d2623e5959 class=n-a></a>Mansouri M, Bellon-Echeverria I, Rizk A, <i> et al.</i>: Highly efficient baculovirus-mediated multigene delivery in primary cells. <i>Nat Commun.</i> 2016; <b>7</b>: 11529. <a target=xrefwindow id=d2623e5970 href="http://www.ncbi.nlm.nih.gov/pubmed/27143231">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5973 href="http://dx.doi.org/10.1038/ncomms11529">Publisher Full Text </a> | <a target=xrefwindow id=d2623e5977 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4857464">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d2623e5986 class=n-a></a>Chen X, Gonçalves MA: Engineered Viruses as Genome Editing Devices. <i>Mol Ther.</i> 2016; <b>24</b>(3): 447–57. <a target=xrefwindow id=d2623e5994 href="http://www.ncbi.nlm.nih.gov/pubmed/26336974">PubMed Abstract </a> | <a target=xrefwindow id=d2623e5997 href="http://dx.doi.org/10.1038/mt.2015.164">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6000 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4786910">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d2623e6009 class=n-a></a>Kwang TW, Zeng X, Wang S: Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials. <i>Mol Ther Methods Clin Dev.</i> 2016; <b>3</b>: 15050. <a target=xrefwindow id=d2623e6017 href="http://www.ncbi.nlm.nih.gov/pubmed/26858963">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6020 href="http://dx.doi.org/10.1038/mtm.2015.50">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6023 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4729316">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d2623e6033 class=n-a></a>Epstein BE, Schaffer DV: Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing. <i>Adv Exp Med Biol.</i> 2017; <b>1016</b>: 29–42. <a target=xrefwindow id=d2623e6041 href="http://www.ncbi.nlm.nih.gov/pubmed/29130152">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6044 href="http://dx.doi.org/10.1007/978-3-319-63904-8_2">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6047 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5702533">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d2623e6056 class=n-a></a>Mingozzi F, High KA: Therapeutic <i>in vivo</i> gene transfer for genetic disease using AAV: progress and challenges. <i>Nat Rev Genet.</i> 2011; <b>12</b>(5): 341–55. <a target=xrefwindow id=d2623e6067 href="http://www.ncbi.nlm.nih.gov/pubmed/21499295">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6070 href="http://dx.doi.org/10.1038/nrg2988">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d2623e6079 class=n-a></a>Senís E, Fatouros C, Große S, <i> et al.</i>: CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. <i>Biotechnol J.</i> 2014; <b>9</b>(11): 1402–12. <a target=xrefwindow id=d2623e6090 href="http://www.ncbi.nlm.nih.gov/pubmed/25186301">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6093 href="http://dx.doi.org/10.1002/biot.201400046">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d2623e6102 class=n-a></a>Zhu H, Lau C, Goh S, <i> et al.</i>: Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. <i>Nucleic Acids Res.</i> 2013; <b>41</b>(19): e180. <a target=xrefwindow id=d2623e6113 href="http://www.ncbi.nlm.nih.gov/pubmed/23945944">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6116 href="http://dx.doi.org/10.1093/nar/gkt721">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6120 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3799456">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d2623e6129 class=n-a></a>Joung J, Konermann S, Gootenberg JS, <i> et al.</i>: Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. <i>Nat Protoc.</i> 2017; <b>12</b>(4): 828–63. <a target=xrefwindow id=d2623e6140 href="http://www.ncbi.nlm.nih.gov/pubmed/28333914">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6143 href="http://dx.doi.org/10.1038/nprot.2017.016">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5526071">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727471219"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6156 class=n-a></a>Klann TS, Black JB, Chellappan M, <i> et al.</i>: CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. <i>Nat Biotechnol.</i> 2017; <b>35</b>(6): 561–8. <a target=xrefwindow id=d2623e6167 href="http://www.ncbi.nlm.nih.gov/pubmed/28369033">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6170 href="http://dx.doi.org/10.1038/nbt.3853">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6174 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5462860">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727471219">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d2623e6188 class=n-a></a>Morris SJ, Turner AV, Green N, <i> et al.</i>: Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines. <i>Methods Mol Biol.</i> 2016; <b>1349</b>: 121–35. <a target=xrefwindow id=d2623e6199 href="http://www.ncbi.nlm.nih.gov/pubmed/26458833">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6202 href="http://dx.doi.org/10.1007/978-1-4939-3008-1_8">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d2623e6211 class=n-a></a>Garnier A, Côté J, Nadeau I, <i> et al.</i>: Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. <i>Cytotechnology.</i> 1994; <b>15</b>(1–3): 145–55. <a target=xrefwindow id=d2623e6222 href="http://www.ncbi.nlm.nih.gov/pubmed/7765926">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6225 href="http://dx.doi.org/10.1007/BF00762389">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d2623e6234 class=n-a></a>Fricano-Kugler CJ, Williams MR, Salinaro JR, <i> et al.</i>: Designing, Packaging, and Delivery of High Titer CRISPR Retro and Lentiviruses via Stereotaxic Injection. <i>J Vis Exp.</i> 2016; (111). <a target=xrefwindow id=d2623e6242 href="http://www.ncbi.nlm.nih.gov/pubmed/27285851">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6245 href="http://dx.doi.org/10.3791/53783">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6248 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4927708">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d2623e6257 class=n-a></a>Yi Y, Noh MJ, Lee KH: Current advances in retroviral gene therapy. <i>Curr Gene Ther.</i> 2011; <b>11</b>(3): 218–28. <a target=xrefwindow id=d2623e6265 href="http://www.ncbi.nlm.nih.gov/pubmed/21453283">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6268 href="http://dx.doi.org/10.2174/156652311795684740">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6271 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3182074">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d2623e6280 class=n-a></a>Dropulić B: Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. <i>Hum Gene Ther.</i> 2011; <b>22</b>(6): 649–57. <a target=xrefwindow id=d2623e6288 href="http://www.ncbi.nlm.nih.gov/pubmed/21486177">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6291 href="http://dx.doi.org/10.1089/hum.2011.058">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d2623e6300 class=n-a></a>Mátrai J, Chuah MK, VandenDriessche T: Recent advances in lentiviral vector development and applications. <i>Mol Ther.</i> 2010; <b>18</b>(3): 477–90. <a target=xrefwindow id=d2623e6308 href="http://www.ncbi.nlm.nih.gov/pubmed/20087315">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6311 href="http://dx.doi.org/10.1038/mt.2009.319">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6314 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2839421">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d2623e6324 class=n-a></a>Li C, Guan X, Du T, <i> et al.</i>: Inhibition of HIV-1 infection of primary CD4<sup>+</sup> T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. <i>J Gen Virol.</i> 2015; <b>96</b>(8): 2381–93. <a target=xrefwindow id=d2623e6338 href="http://www.ncbi.nlm.nih.gov/pubmed/25854553">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6342 href="http://dx.doi.org/10.1099/vir.0.000139">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d2623e6351 class=n-a></a>Gwiazda KS, Grier AE, Sahni J, <i> et al.</i>: High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins. <i>Mol Ther.</i> 2016; <b>24</b>(9): 1570–80. <a target=xrefwindow id=d2623e6362 href="http://www.ncbi.nlm.nih.gov/pubmed/27203437">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6365 href="http://dx.doi.org/10.1038/mt.2016.105">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6369 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5113096">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d2623e6378 class=n-a></a>St George JA: Gene therapy progress and prospects: adenoviral vectors. <i>Gene Ther.</i> 2003; <b>10</b>(14): 1135–41. <a target=xrefwindow id=d2623e6386 href="http://www.ncbi.nlm.nih.gov/pubmed/12833122">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6389 href="http://dx.doi.org/10.1038/sj.gt.3302071">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d2623e6398 class=n-a></a>Kochanek S: High-capacity adenoviral vectors for gene transfer and somatic gene therapy. <i>Hum Gene Ther.</i> 1999; <b>10</b>(15): 2451–9. <a target=xrefwindow id=d2623e6406 href="http://www.ncbi.nlm.nih.gov/pubmed/10543611">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6409 href="http://dx.doi.org/10.1089/10430349950016807">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d2623e6418 class=n-a></a>Lusky M: Good manufacturing practice production of adenoviral vectors for clinical trials. <i>Hum Gene Ther.</i> 2005; <b>16</b>(3): 281–91. <a target=xrefwindow id=d2623e6426 href="http://www.ncbi.nlm.nih.gov/pubmed/15812223">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6429 href="http://dx.doi.org/10.1089/hum.2005.16.281">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d2623e6438 class=n-a></a>Volpers C, Kochanek S: Adenoviral vectors for gene transfer and therapy. <i>J Gene Med.</i> 2004; <b>6</b>(Suppl 1): S164–71. <a target=xrefwindow id=d2623e6446 href="http://www.ncbi.nlm.nih.gov/pubmed/14978759">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6449 href="http://dx.doi.org/10.1002/jgm.496">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d2623e6459 class=n-a></a>McConnell MJ, Imperiale MJ: Biology of adenovirus and its use as a vector for gene therapy. <i>Hum Gene Ther.</i> 2004; <b>15</b>(11): 1022–33. <a target=xrefwindow id=d2623e6467 href="http://www.ncbi.nlm.nih.gov/pubmed/15610603">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6470 href="http://dx.doi.org/10.1089/hum.2004.15.1022">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726111852"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6479 class=n-a></a>Yang Y, Wang L, Bell P, <i> et al.</i>: A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. <i>Nat Biotechnol.</i> 2016; <b>34</b>(3): 334–8. <a target=xrefwindow id=d2623e6490 href="http://www.ncbi.nlm.nih.gov/pubmed/26829317">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6493 href="http://dx.doi.org/10.1038/nbt.3469">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6497 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4786489">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726111852">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d2623e6510 class=n-a></a>Chew WL, Tabebordbar M, Cheng JK, <i> et al.</i>: A multifunctional AAV-CRISPR-Cas9 and its host response. <i>Nat Methods.</i> 2016; <b>13</b>(10): 868–74. <a target=xrefwindow id=d2623e6521 href="http://www.ncbi.nlm.nih.gov/pubmed/27595405">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6524 href="http://dx.doi.org/10.1038/nmeth.3993">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6528 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5374744">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d2623e6537 class=n-a></a>During MJ: Adeno-associated virus as a gene delivery system. <i>Adv Drug Deliv Rev.</i> 1997; <b>27</b>(1): 83–94. <a target=xrefwindow id=d2623e6545 href="http://www.ncbi.nlm.nih.gov/pubmed/10837553">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6548 href="http://dx.doi.org/10.1016/S0169-409X(97)00024-0">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d2623e6557 class=n-a></a>Kotterman MA, Schaffer DV: Engineering adeno-associated viruses for clinical gene therapy. <i>Nat Rev Genet.</i> 2014; <b>15</b>(7): 445–51. <a target=xrefwindow id=d2623e6565 href="http://www.ncbi.nlm.nih.gov/pubmed/24840552">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6568 href="http://dx.doi.org/10.1038/nrg3742">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6571 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4393649">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d2623e6580 class=n-a></a>Airenne KJ, Hu YC, Kost TA, <i> et al.</i>: Baculovirus: an insect-derived vector for diverse gene transfer applications. <i>Mol Ther.</i> 2013; <b>21</b>(4): 739–49. <a target=xrefwindow id=d2623e6591 href="http://www.ncbi.nlm.nih.gov/pubmed/23439502">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6594 href="http://dx.doi.org/10.1038/mt.2012.286">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6598 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3616530">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d2623e6608 class=n-a></a>Tabebordbar M, Zhu K, Cheng JKW, <i> et al.</i>: <i>In vivo</i> gene editing in dystrophic mouse muscle and muscle stem cells. <i>Science.</i> 2016; <b>351</b>(6271): 407–11. <a target=xrefwindow id=d2623e6622 href="http://www.ncbi.nlm.nih.gov/pubmed/26721686">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6626 href="http://dx.doi.org/10.1126/science.aad5177">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6629 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4924477">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726050661"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6638 class=n-a></a>Nelson CE, Hakim CH, Ousterout DG, <i> et al.</i>: <i>In vivo</i> genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. <i>Science.</i> 2016; <b>351</b>(6271): 403–7. <a target=xrefwindow id=d2623e6652 href="http://www.ncbi.nlm.nih.gov/pubmed/26721684">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6656 href="http://dx.doi.org/10.1126/science.aad5143">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6659 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4883596">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726050661">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726050662"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6672 class=n-a></a>Long C, Amoasii L, Mireault AA, <i> et al.</i>: Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. <i>Science.</i> 2016; <b>351</b>(6271): 400–3. <a target=xrefwindow id=d2623e6683 href="http://www.ncbi.nlm.nih.gov/pubmed/26721683">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6686 href="http://dx.doi.org/10.1126/science.aad5725">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6690 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4760628">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726050662">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727304044"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6703 class=n-a></a>Bengtsson NE, Hall JK, Odom GL, <i> et al.</i>: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. <i>Nat Commun.</i> 2017; <b>8</b>: 14454. <a target=xrefwindow id=d2623e6714 href="http://www.ncbi.nlm.nih.gov/pubmed/28195574">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6717 href="http://dx.doi.org/10.1038/ncomms14454">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6721 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5316861">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727304044">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727229707"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6734 class=n-a></a>Ruan GX, Barry E, Yu D, <i> et al.</i>: CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10. <i>Mol Ther.</i> 2017; <b>25</b>(2): 331–41. <a target=xrefwindow id=d2623e6745 href="http://www.ncbi.nlm.nih.gov/pubmed/28109959">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6748 href="http://dx.doi.org/10.1016/j.ymthe.2016.12.006">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6752 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5368591">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727229707">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726496362"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6765 class=n-a></a>Hung SS, Chrysostomou V, Li F, <i> et al.</i>: AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells <i>In vivo</i>. <i>Invest Ophthalmol Vis Sci.</i> 2016; <b>57</b>(7): 3470–6. <a target=xrefwindow id=d2623e6779 href="http://www.ncbi.nlm.nih.gov/pubmed/27367513">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6783 href="http://dx.doi.org/10.1167/iovs.16-19316">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726496362">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727401032"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6797 class=n-a></a>Yu W, Mookherjee S, Chaitankar V, <i> et al.</i>: <i>Nrl</i> knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice. <i>Nat Commun.</i> 2017; <b>8</b>: 14716. <a target=xrefwindow id=d2623e6811 href="http://www.ncbi.nlm.nih.gov/pubmed/28291770">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6815 href="http://dx.doi.org/10.1038/ncomms14716">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6818 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5355895">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727401032">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d2623e6831 class=n-a></a>Yin H, Song CQ, Dorkin JR, <i> et al.</i>: Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components <i>in vivo</i>. <i>Nat Biotechnol.</i> 2016; <b>34</b>(3): 328–33. <a target=xrefwindow id=d2623e6845 href="http://www.ncbi.nlm.nih.gov/pubmed/26829318">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6849 href="http://dx.doi.org/10.1038/nbt.3471">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6852 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5423356">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d2623e6861 class=n-a></a>Xie C, Zhang YP, Song L, <i> et al.</i>: Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome. <i>Cell Res.</i> 2016; <b>26</b>(10): 1099–111. <a target=xrefwindow id=d2623e6872 href="http://www.ncbi.nlm.nih.gov/pubmed/27573176">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6875 href="http://dx.doi.org/10.1038/cr.2016.101">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6879 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5113300">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726048045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6888 class=n-a></a>Carroll KJ, Makarewich CA, McAnally J, <i> et al.</i>: A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. <i>Proc Natl Acad Sci U S A.</i> 2016; <b>113</b>(2): 338–43. <a target=xrefwindow id=d2623e6899 href="http://www.ncbi.nlm.nih.gov/pubmed/26719419">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6902 href="http://dx.doi.org/10.1073/pnas.1523918113">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6906 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4720342">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726048045">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730126996"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6919 class=n-a></a>Johansen AK, Molenaar B, Versteeg D, <i> et al.</i>: Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption. <i>Circ Res.</i> 2017; <b>121</b>(10): 1168–81. <a target=xrefwindow id=d2623e6930 href="http://www.ncbi.nlm.nih.gov/pubmed/28851809">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6933 href="http://dx.doi.org/10.1161/CIRCRESAHA.116.310370">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730126996">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718892278"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6946 class=n-a></a>Platt RJ, Chen S, Zhou Y, <i> et al.</i>: CRISPR-Cas9 knockin mice for genome editing and cancer modeling. <i>Cell.</i> 2014; <b>159</b>(2): 440–55. <a target=xrefwindow id=d2623e6957 href="http://www.ncbi.nlm.nih.gov/pubmed/25263330">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6960 href="http://dx.doi.org/10.1016/j.cell.2014.09.014">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6964 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4265475">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718892278">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725579684"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e6978 class=n-a></a>Kleinstiver BP, Prew MS, Tsai SQ, <i> et al.</i>: Engineered CRISPR-Cas9 nucleases with altered PAM specificities. <i>Nature.</i> 2015; <b>523</b>(7561): 481–5. <a target=xrefwindow id=d2623e6989 href="http://www.ncbi.nlm.nih.gov/pubmed/26098369">PubMed Abstract </a> | <a target=xrefwindow id=d2623e6992 href="http://dx.doi.org/10.1038/nature14592">Publisher Full Text </a> | <a target=xrefwindow id=d2623e6996 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4540238">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725579684">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718277941"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7009 class=n-a></a>Nishimasu H, Ran FA, Hsu PD, <i> et al.</i>: Crystal structure of Cas9 in complex with guide RNA and target DNA. <i>Cell.</i> 2014; <b>156</b>(5): 935–49. <a target=xrefwindow id=d2623e7020 href="http://www.ncbi.nlm.nih.gov/pubmed/24529477">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7023 href="http://dx.doi.org/10.1016/j.cell.2014.02.001">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7027 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4139937">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718277941">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726829911"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7040 class=n-a></a>Tervo DG, Hwang B, Viswanathan S, <i> et al.</i>: A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. <i>Neuron.</i> 2016; <b>92</b>(2): 372–82. <a target=xrefwindow id=d2623e7051 href="http://www.ncbi.nlm.nih.gov/pubmed/27720486">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7054 href="http://dx.doi.org/10.1016/j.neuron.2016.09.021">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726829911">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727815117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7067 class=n-a></a>Kemaladewi DU, Maino E, Hyatt E, <i> et al.</i>: Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. <i>Nat Med.</i> 2017; <b>23</b>(8): 984–9. <a target=xrefwindow id=d2623e7078 href="http://www.ncbi.nlm.nih.gov/pubmed/28714989">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7081 href="http://dx.doi.org/10.1038/nm.4367">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727815117">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d2623e7094 class=n-a></a>El Refaey M, Xu L, Gao Y, <i> et al.</i>: <i>In vivo</i> Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice. <i>Circ Res.</i> 2017; <b>121</b>(8): 923–9. <a target=xrefwindow id=d2623e7108 href="http://www.ncbi.nlm.nih.gov/pubmed/28790199">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7112 href="http://dx.doi.org/10.1161/CIRCRESAHA.117.310996">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7115 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5623072">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d2623e7124 class=n-a></a>Ohmori T, Nagao Y, Mizukami H, <i> et al.</i>: CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. <i>Sci Rep.</i> 2017; <b>7</b>(1): 4159. <a target=xrefwindow id=d2623e7135 href="http://www.ncbi.nlm.nih.gov/pubmed/28646206">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7138 href="http://dx.doi.org/10.1038/s41598-017-04625-5">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5482879">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727471680"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7152 class=n-a></a>Yin C, Zhang T, Qu X, <i> et al.</i>: <i>In vivo</i> Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. <i>Mol Ther.</i> 2017; <b>25</b>(5): 1168–86. <a target=xrefwindow id=d2623e7166 href="http://www.ncbi.nlm.nih.gov/pubmed/28366764">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7170 href="http://dx.doi.org/10.1016/j.ymthe.2017.03.012">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7173 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5417847">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727471680">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718252428"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7186 class=n-a></a>Fu Y, Sander JD, Reyon D, <i> et al.</i>: Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. <i>Nat Biotechnol.</i> 2014; <b>32</b>(3): 279–84. <a target=xrefwindow id=d2623e7197 href="http://www.ncbi.nlm.nih.gov/pubmed/24463574">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7200 href="http://dx.doi.org/10.1038/nbt.2808">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7204 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3988262">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718252428">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d2623e7217 class=n-a></a>Davis KM, Pattanayak V, Thompson DB, <i> et al.</i>: Small molecule-triggered Cas9 protein with improved genome-editing specificity. <i>Nat Chem Biol.</i> 2015; <b>11</b>(5): 316–8. <a target=xrefwindow id=d2623e7228 href="http://www.ncbi.nlm.nih.gov/pubmed/25848930">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7231 href="http://dx.doi.org/10.1038/nchembio.1793">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7235 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4402137">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725340884"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7244 class=n-a></a>Yu C, Liu Y, Ma T, <i> et al.</i>: Small molecules enhance CRISPR genome editing in pluripotent stem cells. <i>Cell Stem Cell.</i> 2015; <b>16</b>(2): 142–7. <a target=xrefwindow id=d2623e7255 href="http://www.ncbi.nlm.nih.gov/pubmed/25658371">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7258 href="http://dx.doi.org/10.1016/j.stem.2015.01.003">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7262 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4461869">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725340884">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d2623e7275 class=n-a></a>Monteys AM, Ebanks SA, Keiser MS, <i> et al.</i>: CRISPR/Cas9 Editing of the Mutant Huntingtin Allele <i>In Vitro</i> and <i>In Vivo</i>. <i>Mol Ther.</i> 2017; <b>25</b>(1): 12–23. <a target=xrefwindow id=d2623e7293 href="http://www.ncbi.nlm.nih.gov/pubmed/28129107">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7296 href="http://dx.doi.org/10.1016/j.ymthe.2016.11.010">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5363210">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d2623e7308 class=n-a></a>Jarrett KE, Lee CM, Yeh YH, <i> et al.</i>: Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. <i>Sci Rep.</i> 2017; <b>7</b>: 44624. <a target=xrefwindow id=d2623e7319 href="http://www.ncbi.nlm.nih.gov/pubmed/28300165">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7322 href="http://dx.doi.org/10.1038/srep44624">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7326 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5353616">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d2623e7336 class=n-a></a>Guo Y, VanDusen NJ, Zhang L, <i> et al.</i>: Analysis of Cardiac Myocyte Maturation Using CASAAV, a Platform for Rapid Dissection of Cardiac Myocyte Gene Function <i>In Vivo</i>. <i>Circ Res.</i> 2017; <b>120</b>(12): 1874–88. <a target=xrefwindow id=d2623e7350 href="http://www.ncbi.nlm.nih.gov/pubmed/28356340">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7354 href="http://dx.doi.org/10.1161/CIRCRESAHA.116.310283">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7357 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5466492">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728639298"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7366 class=n-a></a>Chow RD, Guzman CD, Wang G, <i> et al.</i>: AAV-mediated direct <i>in vivo</i> CRISPR screen identifies functional suppressors in glioblastoma. <i>Nat Neurosci.</i> 2017; <b>20</b>(10): 1329–41. <a target=xrefwindow id=d2623e7380 href="http://www.ncbi.nlm.nih.gov/pubmed/28805815">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7384 href="http://dx.doi.org/10.1038/nn.4620">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7387 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5614841">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728639298">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726593736"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7400 class=n-a></a>Murlidharan G, Sakamoto K, Rao L, <i> et al.</i>: CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. <i>Mol Ther Nucleic Acids.</i> 2016; <b>5</b>(7): e338. <a target=xrefwindow id=d2623e7411 href="http://www.ncbi.nlm.nih.gov/pubmed/27434683">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7414 href="http://dx.doi.org/10.1038/mtna.2016.49">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7418 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5330941">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726593736">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726705702"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7431 class=n-a></a>de Solis CA, Ho A, Holehonnur R, <i> et al.</i>: The Development of a Viral Mediated CRISPR/Cas9 System with Doxycycline Dependent gRNA Expression for Inducible <i>In vitro</i> and <i>In vivo</i> Genome Editing. <i>Front Mol Neurosci.</i> 2016; <b>9</b>: 70. <a target=xrefwindow id=d2623e7449 href="http://www.ncbi.nlm.nih.gov/pubmed/27587996">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7452 href="http://dx.doi.org/10.3389/fnmol.2016.00070">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7455 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4988984">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726705702">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d2623e7468 class=n-a></a>Nishiyama J, Mikuni T, Yasuda R: Virus-Mediated Genome Editing via Homology-Directed Repair in Mitotic and Postmitotic Cells in Mammalian Brain. <i>Neuron.</i> 2017; <b>96</b>(4): 755–768.e5. <a target=xrefwindow id=d2623e7476 href="http://www.ncbi.nlm.nih.gov/pubmed/29056297">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7479 href="http://dx.doi.org/10.1016/j.neuron.2017.10.004">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7482 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5691606">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d2623e7491 class=n-a></a>Li Y, Kim J: Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus. <i>Neuroscience.</i> 2017; <b>363</b>: 11–25. <a target=xrefwindow id=d2623e7499 href="http://www.ncbi.nlm.nih.gov/pubmed/28888955">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7502 href="http://dx.doi.org/10.1016/j.neuroscience.2017.08.053">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d2623e7512 class=n-a></a>Lin H, Hu H, Duan W, <i> et al.</i>: Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase. <i>Mol Neurobiol.</i> 2016; 1–14. <a target=xrefwindow id=d2623e7520 href="http://www.ncbi.nlm.nih.gov/pubmed/27995572">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7523 href="http://dx.doi.org/10.1007/s12035-016-0335-z">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d2623e7532 class=n-a></a>Huang X, Zhou G, Wu W, <i> et al.</i>: Genome editing abrogates angiogenesis <i>in vivo</i>. <i>Nat Commun.</i> 2017; <b>8</b>(1): 112. <a target=xrefwindow id=d2623e7546 href="http://www.ncbi.nlm.nih.gov/pubmed/28740073">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7550 href="http://dx.doi.org/10.1038/s41467-017-00140-3">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7553 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5524639">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726366657"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7562 class=n-a></a>Kaminski R, Bella R, Yin C, <i> et al.</i>: Excision of HIV-1 DNA by gene editing: a proof-of-concept <i>in vivo</i> study. <i>Gene Ther.</i> 2016; <b>23</b>(8–9): 690–5. <a target=xrefwindow id=d2623e7576 href="http://www.ncbi.nlm.nih.gov/pubmed/27194423">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7580 href="http://dx.doi.org/10.1038/gt.2016.41">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7583 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4974122">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726366657">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1116360"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e7596 class=n-a></a>Grimm D, Lee JS, Wang L, <i> et al.</i>: <i>In vitro</i> and <i>in vivo</i> gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. <i>J Virol.</i> 2008; <b>82</b>(12): 5887–911. <a target=xrefwindow id=d2623e7614 href="http://www.ncbi.nlm.nih.gov/pubmed/18400866">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7617 href="http://dx.doi.org/10.1128/JVI.00254-08">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7620 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2395137">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1116360">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d2623e7633 class=n-a></a>Hashimoto H, Mizushima T, Chijiwa T, <i> et al.</i>: Efficient production of recombinant adeno-associated viral vector, serotype DJ/8, carrying the GFP gene. <i>Virus Res.</i> 2017; <b>238</b>: 63–8. <a target=xrefwindow id=d2623e7644 href="http://www.ncbi.nlm.nih.gov/pubmed/28571759">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7647 href="http://dx.doi.org/10.1016/j.virusres.2017.05.017">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d2623e7656 class=n-a></a>Iida A, Takino N, Miyauchi H, <i> et al.</i>: Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice. <i>Biomed Res Int.</i> 2013; <b>2013</b>: 974819. <a target=xrefwindow id=d2623e7667 href="http://www.ncbi.nlm.nih.gov/pubmed/23762870">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7670 href="http://dx.doi.org/10.1155/2013/974819">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7674 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3671507">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d2623e7684 class=n-a></a>McCarty DM, Monahan PE, Samulski RJ: Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. <i>Gene Ther.</i> 2001; <b>8</b>(16): 1248–54. <a target=xrefwindow id=d2623e7692 href="http://www.ncbi.nlm.nih.gov/pubmed/11509958">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7695 href="http://dx.doi.org/10.1038/sj.gt.3301514">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d2623e7704 class=n-a></a>Wang X, Xu Z, Tian Z, <i> et al.</i>: The EF-1α promoter maintains high-level transgene expression from episomal vectors in transfected CHO-K1 cells. <i>J Cell Mol Med.</i> 2017; <b>21</b>(11): 3044–54. <a target=xrefwindow id=d2623e7715 href="http://www.ncbi.nlm.nih.gov/pubmed/28557288">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7718 href="http://dx.doi.org/10.1111/jcmm.13216">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7722 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5661254">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d2623e7731 class=n-a></a>Teschendorf C, Warrington KH Jr, Siemann DW, <i> et al.</i>: Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. <i>Anticancer Res.</i> 2002; <b>22</b>(6A): 3325–30. <a target=xrefwindow id=d2623e7742 href="http://www.ncbi.nlm.nih.gov/pubmed/12530082">PubMed Abstract </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d2623e7751 class=n-a></a>Chung S, Andersson T, Sonntag KC, <i> et al.</i>: Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines. <i>Stem Cells.</i> 2002; <b>20</b>(2): 139–45. <a target=xrefwindow id=d2623e7762 href="http://www.ncbi.nlm.nih.gov/pubmed/11897870">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7765 href="http://dx.doi.org/10.1634/stemcells.20-2-139">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7769 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2615228">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d2623e7778 class=n-a></a>Roelz R, Pilz IH, Mutschler M, <i> et al.</i>: Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells. <i>Exp Hematol.</i> 2010; <b>38</b>(9): 792–7. <a target=xrefwindow id=d2623e7789 href="http://www.ncbi.nlm.nih.gov/pubmed/20685233">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7792 href="http://dx.doi.org/10.1016/j.exphem.2010.05.005">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d2623e7801 class=n-a></a>Mäkinen PI, Koponen JK, Kärkkäinen AM, <i> et al.</i>: Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. <i>J Gene Med.</i> 2006; <b>8</b>(4): 433–41. <a target=xrefwindow id=d2623e7812 href="http://www.ncbi.nlm.nih.gov/pubmed/16389634">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7815 href="http://dx.doi.org/10.1002/jgm.860">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d2623e7825 class=n-a></a>Sun CP, Wu TH, Chen CC, <i> et al.</i>: Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference. <i>Hum Gene Ther.</i> 2013; <b>24</b>(8): 739–50. <a target=xrefwindow id=d2623e7836 href="http://www.ncbi.nlm.nih.gov/pubmed/23829557">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7839 href="http://dx.doi.org/10.1089/hum.2012.239">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7843 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3747597">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d2623e7852 class=n-a></a>Larson MH, Gilbert LA, Wang X, <i> et al.</i>: CRISPR interference (CRISPRi) for sequence-specific control of gene expression. <i>Nat Protoc.</i> 2013; <b>8</b>(11): 2180–96. <a target=xrefwindow id=d2623e7863 href="http://www.ncbi.nlm.nih.gov/pubmed/24136345">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7866 href="http://dx.doi.org/10.1038/nprot.2013.132">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7870 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3922765">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d2623e7879 class=n-a></a>Ranganathan V, Wahlin K, Maruotti J, <i> et al.</i>: Expansion of the CRISPR-Cas9 genome targeting space through the use of H1 promoter-expressed guide RNAs. <i>Nat Commun.</i> 2014; <b>5</b>: 4516. <a target=xrefwindow id=d2623e7890 href="http://www.ncbi.nlm.nih.gov/pubmed/25105359">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7893 href="http://dx.doi.org/10.1038/ncomms5516">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7897 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4133144">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d2623e7906 class=n-a></a>Vidigal JA, Ventura A: Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries. <i>Nat Commun.</i> 2015; <b>6</b>: 8083. <a target=xrefwindow id=d2623e7914 href="http://www.ncbi.nlm.nih.gov/pubmed/26278926">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7917 href="http://dx.doi.org/10.1038/ncomms9083">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7920 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4544769">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d2623e7929 class=n-a></a>Saraiva J, Nobre RJ, Pereira de Almeida L: Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. <i>J Control Release.</i> 2016; <b>241</b>: 94–109. <a target=xrefwindow id=d2623e7937 href="http://www.ncbi.nlm.nih.gov/pubmed/27637390">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7940 href="http://dx.doi.org/10.1016/j.jconrel.2016.09.011">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d2623e7949 class=n-a></a>Vagner T, Dvorzhak A, Wójtowicz AM, <i> et al.</i>: Systemic application of AAV vectors targeting GFAP-expressing astrocytes in Z-Q175-KI Huntington's disease mice. <i>Mol Cell Neurosci.</i> 2016; <b>77</b>: 76–86. <a target=xrefwindow id=d2623e7960 href="http://www.ncbi.nlm.nih.gov/pubmed/27989734">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7963 href="http://dx.doi.org/10.1016/j.mcn.2016.10.007">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d2623e7973 class=n-a></a>Tanguy Y, Biferi MG, Besse A, <i> et al.</i>: Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. <i>Front Mol Neurosci.</i> 2015; <b>8</b>: 36. <a target=xrefwindow id=d2623e7984 href="http://www.ncbi.nlm.nih.gov/pubmed/26283910">PubMed Abstract </a> | <a target=xrefwindow id=d2623e7987 href="http://dx.doi.org/10.3389/fnmol.2015.00036">Publisher Full Text </a> | <a target=xrefwindow id=d2623e7991 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4516891">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d2623e8000 class=n-a></a>Cyranoski D: CRISPR gene-editing tested in a person for the first time. <i>Nature.</i> 2016; <b>539</b>(7630): 479. <a target=xrefwindow id=d2623e8008 href="http://www.ncbi.nlm.nih.gov/pubmed/27882996">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8011 href="http://dx.doi.org/10.1038/nature.2016.20988">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d2623e8020 class=n-a></a>Cyranoski D: Chinese scientists to pioneer first human CRISPR trial. <i>Nature.</i> 2016; <b>535</b>(7613): 476–7. <a target=xrefwindow id=d2623e8028 href="http://www.ncbi.nlm.nih.gov/pubmed/27466105">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8031 href="http://dx.doi.org/10.1038/nature.2016.20302">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d2623e8040 class=n-a></a>Costa R, Carneiro BA, Agulnik M, <i> et al.</i>: Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. <i>Oncotarget.</i> 2017; <b>8</b>(5): 8910–20. <a target=xrefwindow id=d2623e8051 href="http://www.ncbi.nlm.nih.gov/pubmed/27852042">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8054 href="http://dx.doi.org/10.18632/oncotarget.13315">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8058 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5352453">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d2623e8067 class=n-a></a>Zhang T, Xie J, Arai S, <i> et al.</i>: The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget.</i> 2016; <b>7</b>(45): 73068–79. <a target=xrefwindow id=d2623e8078 href="http://www.ncbi.nlm.nih.gov/pubmed/27683031">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8081 href="http://dx.doi.org/10.18632/oncotarget.12230">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8085 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5341964">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d2623e8094 class=n-a></a>Zhong L, Li B, Mah CS, <i> et al.</i>: Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. <i>Proc Natl Acad Sci U S A.</i> 2008; <b>105</b>(22): 7827–32. <a target=xrefwindow id=d2623e8105 href="http://www.ncbi.nlm.nih.gov/pubmed/18511559">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8108 href="http://dx.doi.org/10.1073/pnas.0802866105">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2402387">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d2623e8122 class=n-a></a>Ling C, Li B, Ma W, <i> et al.</i>: Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses. <i>Hum Gene Ther Methods.</i> 2016; <b>27</b>(4): 143–9. <a target=xrefwindow id=d2623e8133 href="http://www.ncbi.nlm.nih.gov/pubmed/27431826">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8136 href="http://dx.doi.org/10.1089/hgtb.2016.054">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8140 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4991608">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d2623e8149 class=n-a></a>Kim D, Kim S, Kim S, <i> et al.</i>: Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq. <i>Genome Res.</i> 2016; <b>26</b>(3): 406–15. <a target=xrefwindow id=d2623e8160 href="http://www.ncbi.nlm.nih.gov/pubmed/26786045">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8163 href="http://dx.doi.org/10.1101/gr.199588.115">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8167 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4772022">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d2623e8176 class=n-a></a>Kim D, Bae S, Park J, <i> et al.</i>: Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. <i>Nat Methods.</i> 2015; <b>12</b>(3): 237–43, 1 p following 243. <a target=xrefwindow id=d2623e8187 href="http://www.ncbi.nlm.nih.gov/pubmed/25664545">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8190 href="http://dx.doi.org/10.1038/nmeth.3284">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d2623e8199 class=n-a></a>Kuscu C, Arslan S, Singh R, <i> et al.</i>: Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. <i>Nat Biotechnol.</i> 2014; <b>32</b>(7): 677–83. <a target=xrefwindow id=d2623e8210 href="http://www.ncbi.nlm.nih.gov/pubmed/24837660">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8213 href="http://dx.doi.org/10.1038/nbt.2916">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725367733"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8222 class=n-a></a>O'Geen H, Henry IM, Bhakta MS, <i> et al.</i>: A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture. <i>Nucleic Acids Res.</i> 2015; <b>43</b>(6): 3389–404. <a target=xrefwindow id=d2623e8233 href="http://www.ncbi.nlm.nih.gov/pubmed/25712100">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8236 href="http://dx.doi.org/10.1093/nar/gkv137">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8240 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4381059">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725367733">F1000 Recommendation</a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725275523"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8253 class=n-a></a>Tsai SQ, Zheng Z, Nguyen NT, <i> et al.</i>: GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. <i>Nat Biotechnol.</i> 2015; <b>33</b>(2): 187–97. <a target=xrefwindow id=d2623e8264 href="http://www.ncbi.nlm.nih.gov/pubmed/25513782">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8267 href="http://dx.doi.org/10.1038/nbt.3117">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8271 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4320685">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725275523">F1000 Recommendation</a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d2623e8285 class=n-a></a>Yang L, Grishin D, Wang G, <i> et al.</i>: Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. <i>Nat Commun.</i> 2014; <b>5</b>: 5507. <a target=xrefwindow id=d2623e8296 href="http://www.ncbi.nlm.nih.gov/pubmed/25425480">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8299 href="http://dx.doi.org/10.1038/ncomms6507">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8303 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4352754">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d2623e8312 class=n-a></a>Morgens DW, Wainberg M, Boyle EA, <i> et al.</i>: Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. <i>Nat Commun.</i> 2017; <b>8</b>: 15178. <a target=xrefwindow id=d2623e8323 href="http://www.ncbi.nlm.nih.gov/pubmed/28474669">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8326 href="http://dx.doi.org/10.1038/ncomms15178">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8330 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5424143">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d2623e8339 class=n-a></a>Cameron P, Fuller CK, Donohoue PD, <i> et al.</i>: Mapping the genomic landscape of CRISPR-Cas9 cleavage. <i>Nat Methods.</i> 2017; <b>14</b>(6): 600–6. <a target=xrefwindow id=d2623e8350 href="http://www.ncbi.nlm.nih.gov/pubmed/28459459">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8353 href="http://dx.doi.org/10.1038/nmeth.4284">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d2623e8362 class=n-a></a>Scott DA, Zhang F: Implications of human genetic variation in CRISPR-based therapeutic genome editing. <i>Nat Med.</i> 2017; <b>23</b>(9): 1095–101. <a target=xrefwindow id=d2623e8370 href="http://www.ncbi.nlm.nih.gov/pubmed/28759051">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8373 href="http://dx.doi.org/10.1038/nm.4377">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727567316"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8382 class=n-a></a>Tsai SQ, Nguyen NT, Malagon-Lopez J, <i> et al.</i>: CIRCLE-seq: a highly sensitive <i>in vitro</i> screen for genome-wide CRISPR-Cas9 nuclease off-targets. <i>Nat Methods.</i> 2017; <b>14</b>(6): 607–14. <a target=xrefwindow id=d2623e8396 href="http://www.ncbi.nlm.nih.gov/pubmed/28459458">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8400 href="http://dx.doi.org/10.1038/nmeth.4278">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727567316">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d2623e8413 class=n-a></a>Kim D, Lim K, Kim ST, <i> et al.</i>: Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. <i>Nat Biotechnol.</i> 2017; <b>35</b>(5): 475–80. <a target=xrefwindow id=d2623e8424 href="http://www.ncbi.nlm.nih.gov/pubmed/28398345">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8427 href="http://dx.doi.org/10.1038/nbt.3852">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d2623e8437 class=n-a></a>Koo T, Lee J, Kim JS: Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9. <i>Mol Cells.</i> 2015; <b>38</b>(6): 475–81. <a target=xrefwindow id=d2623e8445 href="http://www.ncbi.nlm.nih.gov/pubmed/25985872">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8448 href="http://dx.doi.org/10.14348/molcells.2015.0103">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8451 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4469905">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728639308"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8460 class=n-a></a>Batra R, Nelles DA, Pirie E, <i> et al.</i>: Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. <i>Cell.</i> 2017; <b>170</b>(5): 899–912.e10. <a target=xrefwindow id=d2623e8471 href="http://www.ncbi.nlm.nih.gov/pubmed/28803727">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8474 href="http://dx.doi.org/10.1016/j.cell.2017.07.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728639308">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732025728"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8487 class=n-a></a>Pinto BS, Saxena T, Oliveira R, <i> et al.</i>: Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9. <i>Mol Cell.</i> 2017; <b>68</b>(3): 479–490.e5. <a target=xrefwindow id=d2623e8498 href="http://www.ncbi.nlm.nih.gov/pubmed/29056323">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8501 href="http://dx.doi.org/10.1016/j.molcel.2017.09.033">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732025728">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d2623e8514 class=n-a></a>Kim K, Park SW, Kim JH, <i> et al.</i>: Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. <i>Genome Res.</i> 2017; <b>27</b>(3): 419–26. <a target=xrefwindow id=d2623e8525 href="http://www.ncbi.nlm.nih.gov/pubmed/28209587">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8528 href="http://dx.doi.org/10.1101/gr.219089.116">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8532 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5340969">Free Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d2623e8541 class=n-a></a>Nihongaki Y, Kawano F, Nakajima T, <i> et al.</i>: Photoactivatable CRISPR-Cas9 for optogenetic genome editing. <i>Nat Biotechnol.</i> 2015; <b>33</b>(7): 755–60. <a target=xrefwindow id=d2623e8552 href="http://www.ncbi.nlm.nih.gov/pubmed/26076431">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8555 href="http://dx.doi.org/10.1038/nbt.3245">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725348560"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8564 class=n-a></a>Polstein LR, Gersbach CA: A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. <i>Nat Chem Biol.</i> 2015; <b>11</b>(3): 198–200. <a target=xrefwindow id=d2623e8572 href="http://www.ncbi.nlm.nih.gov/pubmed/25664691">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8575 href="http://dx.doi.org/10.1038/nchembio.1753">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8578 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4412021">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725348560">F1000 Recommendation</a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d2623e8592 class=n-a></a>Dow LE, Fisher J, O'Rourke KP, <i> et al.</i>: Inducible <i>in vivo</i> genome editing with CRISPR-Cas9. <i>Nat Biotechnol.</i> 2015; <b>33</b>(4): 390–4. <a target=xrefwindow id=d2623e8606 href="http://www.ncbi.nlm.nih.gov/pubmed/25690852">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8610 href="http://dx.doi.org/10.1038/nbt.3155">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8613 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4390466">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d2623e8622 class=n-a></a>Liu KI, Ramli MN, Woo CW, <i> et al.</i>: A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing. <i>Nat Chem Biol.</i> 2016; <b>12</b>(11): 980–7. <a target=xrefwindow id=d2623e8633 href="http://www.ncbi.nlm.nih.gov/pubmed/27618190">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8636 href="http://dx.doi.org/10.1038/nchembio.2179">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d2623e8645 class=n-a></a>Liu Y, Zeng Y, Liu L, <i> et al.</i>: Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. <i>Nat Commun.</i> 2014; <b>5</b>: 5393. <a target=xrefwindow id=d2623e8656 href="http://www.ncbi.nlm.nih.gov/pubmed/25373919">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8659 href="http://dx.doi.org/10.1038/ncomms6393">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d2623e8668 class=n-a></a>Weinberg BH, Pham NT, Caraballo LD, <i> et al.</i>: Large-scale design of robust genetic circuits with multiple inputs and outputs for mammalian cells. <i>Nat Biotechnol.</i> 2017; <b>35</b>(5): 453–62. <a target=xrefwindow id=d2623e8679 href="http://www.ncbi.nlm.nih.gov/pubmed/28346402">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8682 href="http://dx.doi.org/10.1038/nbt.3805">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8686 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5423837">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d2623e8695 class=n-a></a>Shen B, Zhang W, Zhang J, <i> et al.</i>: Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. <i>Nat Methods.</i> 2014; <b>11</b>(4): 399–402. <a target=xrefwindow id=d2623e8706 href="http://www.ncbi.nlm.nih.gov/pubmed/24584192">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8709 href="http://dx.doi.org/10.1038/nmeth.2857">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d2623e8718 class=n-a></a>Cho SW, Kim S, Kim Y, <i> et al.</i>: Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. <i>Genome Res.</i> 2014; <b>24</b>(1): 132–41. <a target=xrefwindow id=d2623e8729 href="http://www.ncbi.nlm.nih.gov/pubmed/24253446">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8732 href="http://dx.doi.org/10.1101/gr.162339.113">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8736 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3875854">Free Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718095657"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8746 class=n-a></a>Ran FA, Hsu PD, Lin CY, <i> et al.</i>: Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. <i>Cell.</i> 2013; <b>154</b>(6): 1380–9. <a target=xrefwindow id=d2623e8757 href="http://www.ncbi.nlm.nih.gov/pubmed/23992846">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8760 href="http://dx.doi.org/10.1016/j.cell.2013.08.021">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8764 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3856256">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718095657">F1000 Recommendation</a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d2623e8777 class=n-a></a>Guilinger JP, Thompson DB, Liu DR: Fusion of catalytically inactive Cas9 to <i>FokI</i> nuclease improves the specificity of genome modification. <i>Nat Biotechnol.</i> 2014; <b>32</b>(6): 577–82. <a target=xrefwindow id=d2623e8788 href="http://www.ncbi.nlm.nih.gov/pubmed/24770324">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8791 href="http://dx.doi.org/10.1038/nbt.2909">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8795 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4263420">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726058228"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8804 class=n-a></a>Kleinstiver BP, Pattanayak V, Prew MS, <i> et al.</i>: High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. <i>Nature.</i> 2016; <b>529</b>(7587): 490–5. <a target=xrefwindow id=d2623e8815 href="http://www.ncbi.nlm.nih.gov/pubmed/26735016">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8818 href="http://dx.doi.org/10.1038/nature16526">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8822 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4851738">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726058228">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725974865"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8835 class=n-a></a>Slaymaker IM, Gao L, Zetsche B, <i> et al.</i>: Rationally engineered Cas9 nucleases with improved specificity. <i>Science.</i> 2016; <b>351</b>(6268): 84–8. <a target=xrefwindow id=d2623e8846 href="http://www.ncbi.nlm.nih.gov/pubmed/26628643">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8849 href="http://dx.doi.org/10.1126/science.aad5227">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8853 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4714946">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725974865">F1000 Recommendation</a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d2623e8866 class=n-a></a>Chen JS, Dagdas YS, Kleinstiver BP, <i> et al.</i>: Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. <i>Nature.</i> 2017; <b>550</b>(7676): 407–10. <a target=xrefwindow id=d2623e8877 href="http://www.ncbi.nlm.nih.gov/pubmed/28931002">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8880 href="http://dx.doi.org/10.1038/nature24268">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726297168"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8889 class=n-a></a>Komor AC, Kim YB, Packer MS, <i> et al.</i>: Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. <i>Nature.</i> 2016; <b>533</b>(7603): 420–4. <a target=xrefwindow id=d2623e8900 href="http://www.ncbi.nlm.nih.gov/pubmed/27096365">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8903 href="http://dx.doi.org/10.1038/nature17946">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8907 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4873371">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726297168">F1000 Recommendation</a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727363082"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8921 class=n-a></a>Kim K, Ryu SM, Kim ST, <i> et al.</i>: Highly efficient RNA-guided base editing in mouse embryos. <i>Nat Biotechnol.</i> 2017; <b>35</b>(5): 435–7. <a target=xrefwindow id=d2623e8932 href="http://www.ncbi.nlm.nih.gov/pubmed/28244995">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8935 href="http://dx.doi.org/10.1038/nbt.3816">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727363082">F1000 Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d2623e8948 class=n-a></a>Richardson CD, Ray GJ, DeWitt MA, <i> et al.</i>: Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. <i>Nat Biotechnol.</i> 2016; <b>34</b>(3): 339–44. <a target=xrefwindow id=d2623e8959 href="http://www.ncbi.nlm.nih.gov/pubmed/26789497">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8962 href="http://dx.doi.org/10.1038/nbt.3481">Publisher Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d2623e8971 class=n-a></a>Song J, Yang D, Xu J, <i> et al.</i>: RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. <i>Nat Commun.</i> 2016; <b>7</b>: 10548. <a target=xrefwindow id=d2623e8982 href="http://www.ncbi.nlm.nih.gov/pubmed/26817820">PubMed Abstract </a> | <a target=xrefwindow id=d2623e8985 href="http://dx.doi.org/10.1038/ncomms10548">Publisher Full Text </a> | <a target=xrefwindow id=d2623e8989 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4738357">Free Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725400493"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e8998 class=n-a></a>Maruyama T, Dougan SK, Truttmann MC, <i> et al.</i>: Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. <i>Nat Biotechnol.</i> 2015; <b>33</b>(5): 538–42. <a target=xrefwindow id=d2623e9009 href="http://www.ncbi.nlm.nih.gov/pubmed/25798939">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9012 href="http://dx.doi.org/10.1038/nbt.3190">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9016 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4618510">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725400493">F1000 Recommendation</a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d2623e9029 class=n-a></a>Cho SW, Kim S, Kim JM, <i> et al.</i>: Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. <i>Nat Biotechnol.</i> 2013; <b>31</b>(3): 230–2. <a target=xrefwindow id=d2623e9040 href="http://www.ncbi.nlm.nih.gov/pubmed/23360966">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9043 href="http://dx.doi.org/10.1038/nbt.2507">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d2623e9052 class=n-a></a>Hendel A, Bak RO, Clark JT, <i> et al.</i>: Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. <i>Nat Biotechnol.</i> 2015; <b>33</b>(9): 985–9. <a target=xrefwindow id=d2623e9063 href="http://www.ncbi.nlm.nih.gov/pubmed/26121415">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9066 href="http://dx.doi.org/10.1038/nbt.3290">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9070 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4729442">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d2623e9080 class=n-a></a>Perez AR, Pritykin Y, Vidigal JA, <i> et al.</i>: GuideScan software for improved single and paired CRISPR guide RNA design. <i>Nat Biotechnol.</i> 2017; <b>35</b>(4): 347–9. <a target=xrefwindow id=d2623e9091 href="http://www.ncbi.nlm.nih.gov/pubmed/28263296">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9094 href="http://dx.doi.org/10.1038/nbt.3804">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9098 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5607865">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d2623e9107 class=n-a></a>Naito Y, Hino K, Bono H, <i> et al.</i>: CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. <i>Bioinformatics.</i> 2015; <b>31</b>(7): 1120–3. <a target=xrefwindow id=d2623e9118 href="http://www.ncbi.nlm.nih.gov/pubmed/25414360">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9121 href="http://dx.doi.org/10.1093/bioinformatics/btu743">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9125 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4382898">Free Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d2623e9134 class=n-a></a>Bae S, Park J, Kim JS: Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. <i>Bioinformatics.</i> 2014; <b>30</b>(10): 1473–5. <a target=xrefwindow id=d2623e9142 href="http://www.ncbi.nlm.nih.gov/pubmed/24463181">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9145 href="http://dx.doi.org/10.1093/bioinformatics/btu048">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4016707">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d2623e9157 class=n-a></a>Zhang XH, Tee LY, Wang XG, <i> et al.</i>: Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. <i>Mol Ther Nucleic Acids.</i> 2015; <b>4</b>(11): e264. <a target=xrefwindow id=d2623e9168 href="http://www.ncbi.nlm.nih.gov/pubmed/26575098">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9171 href="http://dx.doi.org/10.1038/mtna.2015.37">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4877446">Free Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725633584"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e9184 class=n-a></a>Mockenhaupt S, Grosse S, Rupp D, <i> et al.</i>: Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys. <i>Proc Natl Acad Sci U S A.</i> 2015; <b>112</b>(30): E4007–16. <a target=xrefwindow id=d2623e9195 href="http://www.ncbi.nlm.nih.gov/pubmed/26170322">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9198 href="http://dx.doi.org/10.1073/pnas.1510476112">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9202 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4522753">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725633584">F1000 Recommendation</a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d2623e9215 class=n-a></a>Tay FC, Lim JK, Zhu H, <i> et al.</i>: Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. <i>Adv Drug Deliv Rev.</i> 2015; <b>81</b>: 117–27. <a target=xrefwindow id=d2623e9226 href="http://www.ncbi.nlm.nih.gov/pubmed/24859534">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9229 href="http://dx.doi.org/10.1016/j.addr.2014.05.010">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727626073"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e9239 class=n-a></a>Hirosawa M, Fujita Y, Parr CJC, <i> et al.</i>: Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. <i>Nucleic Acids Res.</i> 2017; <b>45</b>(13): e118. <a target=xrefwindow id=d2623e9250 href="http://www.ncbi.nlm.nih.gov/pubmed/28525578">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9253 href="http://dx.doi.org/10.1093/nar/gkx309">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9257 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5570128">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727626073">F1000 Recommendation</a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d2623e9270 class=n-a></a>Manning WC, Zhou S, Bland MP, <i> et al.</i>: Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. <i>Hum Gene Ther.</i> 1998; <b>9</b>(4): 477–85. <a target=xrefwindow id=d2623e9281 href="http://www.ncbi.nlm.nih.gov/pubmed/9525309">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9284 href="http://dx.doi.org/10.1089/hum.1998.9.4-477">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d2623e9293 class=n-a></a>Mingozzi F, Anguela XM, Pavani G, <i> et al.</i>: Overcoming preexisting humoral immunity to AAV using capsid decoys. <i>Sci Transl Med.</i> 2013; <b>5</b>(194): 194ra92. <a target=xrefwindow id=d2623e9304 href="http://www.ncbi.nlm.nih.gov/pubmed/23863832">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9307 href="http://dx.doi.org/10.1126/scitranslmed.3005795">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9311 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4095828">Free Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d2623e9320 class=n-a></a>Huttner NA, Girod A, Perabo L, <i> et al.</i>: Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. <i>Gene Ther.</i> 2003; <b>10</b>(26): 2139–47. <a target=xrefwindow id=d2623e9331 href="http://www.ncbi.nlm.nih.gov/pubmed/14625569">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9334 href="http://dx.doi.org/10.1038/sj.gt.3302123">Publisher Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d2623e9343 class=n-a></a>Arbetman AE, Lochrie M, Zhou S, <i> et al.</i>: Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. <i>J Virol.</i> 2005; <b>79</b>(24): 15238–45. <a target=xrefwindow id=d2623e9354 href="http://www.ncbi.nlm.nih.gov/pubmed/16306595">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9357 href="http://dx.doi.org/10.1128/JVI.79.24.15238-15245.2005">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9361 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1316006">Free Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d2623e9370 class=n-a></a>Maheshri N, Koerber JT, Kaspar BK, <i> et al.</i>: Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. <i>Nat Biotechnol.</i> 2006; <b>24</b>(2): 198–204. <a target=xrefwindow id=d2623e9381 href="http://www.ncbi.nlm.nih.gov/pubmed/16429148">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9384 href="http://dx.doi.org/10.1038/nbt1182">Publisher Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727282386"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2623e9394 class=n-a></a>Bakondi B: <i>In vivo</i> versus <i>ex vivo</i> CRISPR therapies for retinal dystrophy. <i>Expert Rev Ophthalmol.</i> 2016; <b>11</b>(6): 397–400. <a target=xrefwindow id=d2623e9408 href="http://www.ncbi.nlm.nih.gov/pubmed/28163772">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9412 href="http://dx.doi.org/10.1080/17469899.2016.1251316">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9415 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5289756">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727282386">F1000 Recommendation</a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d2623e9428 class=n-a></a>Grimm D, Büning H: Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution. <i>Hum Gene Ther.</i> 2017; <b>28</b>(11): 1075–86. <a target=xrefwindow id=d2623e9436 href="http://www.ncbi.nlm.nih.gov/pubmed/28835125">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9439 href="http://dx.doi.org/10.1089/hum.2017.172">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d2623e9448 class=n-a></a>Paulk NK, Pekrun K, Zhu E, <i> et al.</i>: Bioengineered AAV Capsids with Combined High Human Liver Transduction <i>In vivo</i> and Unique Humoral Seroreactivity. <i>Mol Ther.</i> 2017; pii: S1525-0016(17)30437-9. <a target=xrefwindow id=d2623e9459 href="http://www.ncbi.nlm.nih.gov/pubmed/29055620">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9462 href="http://dx.doi.org/10.1016/j.ymthe.2017.09.021">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d2623e9471 class=n-a></a>Tse LV, Klinc KA, Madigan VJ, <i> et al.</i>: Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. <i>Proc Natl Acad Sci U S A.</i> 2017; <b>114</b>(24): E4812–E4821. <a target=xrefwindow id=d2623e9482 href="http://www.ncbi.nlm.nih.gov/pubmed/28559317">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9485 href="http://dx.doi.org/10.1073/pnas.1704766114">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9489 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5474820">Free Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d2623e9498 class=n-a></a>Li C, Wu S, Albright B, <i> et al.</i>: Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. <i>Mol Ther.</i> 2016; <b>24</b>(1): 53–65. <a target=xrefwindow id=d2623e9509 href="http://www.ncbi.nlm.nih.gov/pubmed/26220272">PubMed Abstract </a> | <a target=xrefwindow id=d2623e9512 href="http://dx.doi.org/10.1038/mt.2015.134">Publisher Full Text </a> | <a target=xrefwindow id=d2623e9516 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4754536">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 20 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2153&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2153&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Mechanical and Biomedical Engineering, City University of Hong Kong, Hong Kong, SAR, China<br/> <sup>2</sup> Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, USA<br/> <sup>3</sup> Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, New York, USA<br/> <sup>4</sup> Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA<br/> <sup>5</sup> Institute for Aging Research, Albert Einstein College of Medicine, Bronx, New York, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-2153/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 20 Dec 2017, 6:2153 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11243.1">https://doi.org/10.12688/f1000research.11243.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Lau CH and Suh Y. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12130 data-id=11243 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11243.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-2153/v1/pdf?article_uuid=1afb21ab-ebd6-4340-9118-10beb7348b60" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11243.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Lau CH and Suh Y. <i>In vivo</i> genome editing in animals using AAV-CRISPR system: applications to translational research of human disease [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2153 (<a href="https://doi.org/10.12688/f1000research.11243.1" target=_blank>https://doi.org/10.12688/f1000research.11243.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11243 id=mobile-track-article-signin-11243 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11243?target=/articles/6-2153"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12130 /> <input name=articleId type=hidden value=11243 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Jin-Soo Kim</strong>, Department of Chemistry, Seoul National University, South Korea </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Dirk Grimm</strong>, Department of Infectious Diseases, Virology, Heidelberg University Hospital, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 20 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2153&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2153&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29021-29026></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29020-29027></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-2153/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>20 Dec 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jin-Soo Kim</strong>, Department of Chemistry, Seoul National University, South Korea </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Dirk Grimm</strong>, Department of Infectious Diseases, Virology, Heidelberg University Hospital, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-2153&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-2153/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "In vivo genome editing in animals using AAV-CRISPR...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-2153/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-2153/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-2153/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Lau CH and Suh Y');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-2153/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-2153",
            templates : {
                twitter : "In vivo genome editing in animals using AAV-CRISPR system: applications.... Lau CH and Suh Y, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-2153/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11243/12130")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12130");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "29026": 0,
                           "29027": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "15209442-93f8-42bd-b3d9-7429dd6bfa19";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2153.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2153.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2153.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-2153.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-2153.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>